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KINETIC MECHANISM AND INHIBITORY STUDY OF PROTEIN ARGININE
METHYLTRANSFERASE 1
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Under the Direction of Professor Yujun George Zheng

ABSTRACT
Protein arginine methyltransferase 1 (PRMT1) is a key posttranslational modification
enzyme that catalyzes the methylation of specific arginine residues in histone and nonhistone
protein substrates, regulating diverse cellular processes such as transcriptional initiation, RNA
splicing, DNA repair, and signal transduction. Recently the essential roles of PRMT1 in cancer
and cardiovascular complications have intrigued much attention. Developing effective PRMT
inhibitors therefore is of significant therapeutic value. The research on PRMT inhibitor
development however is greatly hindered by poor understanding of the biochemical basis of
protein arginine methylation and lack of effective assays for PRMT1 inhibitor screening.
Herein, we report our effort in the kinetic mechanism study as well as the fluorescent
probe and inhibitor development for PRMT1. New fluorescent reporters were designed and
applied to perform single-step analysis of substrate binding and methylation of PRMT1. Using
these reporters, we performed transient-state fluorescence measurements to dissect the rate
constants along the PRMT1 catalytic coordinate. The data give evidence that the chemistry of

methyl transfer is the major rate-limiting step, and that binding of the cofactor SAM or SAH
affects the association and dissociation of H4 with PRMT1. Importantly, we identified a critical
kinetic step suggesting a precatalytic conformational transition induced by substrate binding. On
the other hand, we discovered a type of naphthyl-sulfo (NS) compounds that block PRMT1mediated arginine methylation at micromolar potency through a unique mechanism: they directly
target the substrates but not PRMT enzymes for the observed inhibition. We also found that
suramin, an anti-parasite and anti-cancer drug bearing similar functional groups, effectively
inhibited PRMT1 mediated methylation. These findings about novel PRMT inhibitors and their
unique inhibition mechanism provide a new way for chemical regulation of protein arginine
methylation. Addionally, to dissect the interplaying relationship between different histone
modification marks, we investigated how individual lysine acetylations and their different
combinations at the H4 tail affect Arg-3 methylation in cis. Our data reveal that the effect of
lysine acetylation on arginine methylation depends on the site of acetylation and the type of
methylation. While certain acetylations present a repressive impact on PRMT-1 mediated
methylation (type I methylation), lysine acetylation generally is correlated with enhanced
methylation by PRMT5 (type II dimethylation). In particular, Lys-5 acetylation decreases
activity of PRMT1 but increases that of PRMT5. Furthermore, hyperacetylation increases the
content of ordered secondary structures of H4 tail. These findings provide new insights into the
regulatory mechanism of Arg-3 methylation by H4 acetylation, and unravel that complex
intercommunications exist between different posttranslational marks in cis.
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CHAPTER 1
INTRODUCTION
1.1. The structure and function of chromatin
Exclusively found in eukaryotic cells, chromatin is composed of regularly and intensively
packed DNA and protein. ~146 bp DNA is wrapped around the histone octamer consisting of
two of each of H3, H4, H2A and H2B proteins to form a fundamental repeating genetic element
called nucleosome (Figure 1.1). As the smallest unit of genetic information storage, nucleosomes
are linked by H1 protein and DNA to form compressed chromatin fibers with a beads-on-string
structure. These ~30 nanometer fibers are further coiled into chromosome, which plays
regulatory role in multiple nuclear processes like transcription, replication, DNA repair, mitosis
and apoptosis.(1) The chromatin structure can be changed by epigenetic modifications of DNA
and histones during different phases of cell division.(2-5)
Chromatin is categorized into euchromatin and heterochromatin according to its
conformation and staining state. Euchromatin is loosely packed and stains lightly, and is usually
composed of actively transcribed genes. On the other hand, heterochromatin is tightly packed
and stains intensly, and is mainly composed of inactive genes or satellite sequences, such as
centromere and telomere. H3K9 di and tri-methylation are usually linked with heterochromatin
structure [Zhang MQ et al, BMC Genomics, 2009].
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Figure 1.1. The structure and modification sites of nucleosome in chromatin (6)

1.2. Histone posttranslational modifications
Histones are the major protein components of chromatin, packaging DNA into
nucleosome and helping regulate gene expression. Histones undergo extensive posttranslational
modifications (PTMs) at its amino-terminal tail domain where lie multiple positively charged
residues. Some of these modification sites have been detected by specific antibodies or tandem
mass spectrometry,(7) including lysine acetylation/metylation, arginine methylation, serine
phosphorylation, lysine ubiquitination, etc (Figure 1.2). These modifications represent enormous
potential biological functions (Table 1.1).(8) For example, the residue Lys can be labeled with
mono-, di-, or trimethyl group by various lysine methyltransferases; while the residue Arg can be
marked with mono-, asymmetric di- or symmetric di-methyl group by different protein arginine
methyltransferases (PRMTs).(9, 10) Many of these PTMs profoundly affect the on-and-off status
of gene transcription by recruiting other modulator proteins or factors to initiate the downstream
transcriptional activation or repression. Notably, the specificity of methylation may lead to

3

distinct biological functions, e.g., H3 K4 or K27 methylation (mono-, di-, or tri-) activates
transcription, but H3 K9 methylation (di- or tri-) represses transcription.(11) The molecular
mechanism by which histone PTMs modulate genetic and epigenetic processes is not fully
understood. In particular, how a PTM mark affects the presence and level of other histone
modification marks needs to be addressed and is essential for better understanding the molecular
basis of histone code hypothesis.

ARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKK-

H3

SGRGKGGKGLGKGGAKRHRKC- H4
SGRGKQGGK-

H2A

-K119

PEPAKSAPAPKKGSKKAVTK-

H2B

-K123
K --- Acetylation
K --- Acetylation and methylation
K --- Ubiquitination
R, K --- Methylation
S, T --- Phosphorylation

Figure 1.2. Post-translational modifications on histone N-terminal tail domains

Table 1.1. Different types of histone modifications
Modification

Residue

Function

Related disease

Typical enzyme

Acetylation

Lys

Transcription,

Cancer

p300, pCAF,

Repair
Methylation

Lys, Arg

Tip60(12)

Transcription,

Cancer,

PRMT1, PRMT5

Repair, Splicing

Cardiovascular disease

(13)
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Phosphorylation

Ser, Thr

Transcription,

Cancer

MSK1(14)

Cancer

E1(15)

Repair
Ubiquitylation

Lys

Transcription,
Repair

Sumoylation

Lys

Transcription,

SAE1/SAE2(16)

Nuclear transport

1.3. Histone arginine methylation
Posttranslational modifications (PTMs) are important strategies used by eukaryotic
organisms to modulate their phenotypes. One of the well studied PTMs, arginine methylation, is
catalyzed by protein arginine methyltransferases (PRMTs) with SAM as the methyl donor. The
functions of PRMTs have been broadly studied in different biological processes and diseased
states, but the molecular basis for arginine methylation is not well defined.
Taking Histone H4 arginine 3 (H4R3) methylation as an example, asymmetric
dimethylation of H4R3 mediated by PRMT1 leads to gene activation, while symmetric
dimethylation of H4R3 mediated by PRMT5 is related to gene repression. The two enzymes
introducing these modifications exhibit identifiably similar sequences, but the molecular bases
for their distinct catalytic mechanisms are unclear. A recent report suggested that a conserved
phenylalanine in the active site of PRMT5 is critical for directing the symmetric di-methylation.
(17) It has also been shown that asymmetric dimethylation at H3R17 by CARM1 enhances
transcription activation, that symmetric dimethylation at H3R8 by PRMT5 induces transcription
repression, and that asymmetric dimethylation at H3R2 by PRMT6 leads to gene repression and
is mutually exclusive with H3K4 methylation.
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1.4. Protein arginine methyltransferases
Protein arginine methyltransferases (PRMTs) belong to an important family of
posttranslational modification enzymes that transfer the methyl group from AdoMet (S-adenosyl
methionine, SAM) to specific arginine residues in histone or nonhistone protein substrates. Thus
far, eleven PRMT members have been identified and are categorized into two major types, type I
and type II, according to the substrate and product specificity.(18-20) Type I enzymes (PRMT-1,
-2, -3, -4, -6, and -8) catalyze the transfer of the methyl group from AdoMet to one of the
terminal nitrogen atoms of the guanidino group of specific arginine residues in a protein
substrate, resulting in ω-NG-monomethylarginine (MMA, L-NMMA) and ω-NG,NG-asymmetric
dimethylarginine (ADMA) products.(19, 21-24) Type II enzymes (e.g., PRMT 5, 7, and 9)
catalyze the formation of MMA and ω-NG, N’G-symmetric dimethylarginines (SDMA).(24-27)
A more recent report demonstrated PRMT7 as a Type III enzyme forming only MMA.(28) The
catalytic properties of PRMT-10, and -11 remain to be characterized.
CH3
H2N
CH3
H2N

NH2

H2N

NH

PRMT
type I

(CH2)3

N
H

N
H

NH

(CH2)3

(CH2)3
SAM

O

SAH

N
H

CH3

NH

PRMT
NH

N

SAM

CH3

SAM
SAH

O

O

SAH

HN

NH
NH

PRMT
type II

(CH2)3
N
H

Figure 1.3. Scheme of protein arginine methylation

CH3

O

6

TYPE Histone specifity
1

361

?

PRMT1
1

?

SH3

PRMT2
1

512

Zn2+

PRMT3

?

1

608

PRMT4
1

1

H3R4,17,26,
128,129,131,134

?

H3R8, H4R3

?

H3R2

?

H2A, H4R3

?

H4

375

PRMT6
1

692

PRMT7
1

364

PRMT8
F box

543

Zn2+

?

686

PRMT9
Isoform 2

?
585

PRMT9
Isoform 3

?
1

561

PRMT9
Isoform 4

?
1

H2A, H4

565

PRMT10
PRMT11

?
637

PRMT5

PRMT9
isoform 1

H4R3, H2AR3

423

?
F box

542

?

Figure 1.4. Protein arginine methyltransferasenine family members expressed in human.
Black: conserved catalytic domain. SH3: The SRC homology 3 domain. Zn2+: Zinc finger
binding domain. F box: encoding a protein motif of ~ 50 amino acids as a site of protein-protein
interaction.

Protein arginine methylation is involved in a broad spectrum of biological processes,
including transcriptional activation and repression, mRNA splicing, nuclear─cytoplasmic
shuttling, DNA repair, and signal transduction.(29) The variety of PRMTs’ cellular activities is
partly due to their diverse substrate profiles, including RNA binding proteins (hnRNPa,
fibrillarin, nucleolin, etc.), high molecular weight fibroblast growth factor 2 (HMW FGF-2),
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interleukin enhancer binding factor 3 (ILF3), and histone H3 and H4. Each PRMT enzyme
(PRMT1-9) has a specific set of substrates that partially overlap with the substrates of another
family member. The specificity of PRMTs is demonstrated by the fact that only particular
arginine residues out of all the arginines in a protein substrate are the target methylation sites.
The substrate specificity of PRMTs is determined by the structure of its active site and
peptide binding grooves. PRMT enzymes are composed of a variable N-terminus and a
conserved catalytic core; PRMT4 (CARM1) also contains a unique C-terminal region. So far the
crystal structures of PRMT1, PRMT3 and PRMT4 (CARM1) are available, which are all type I
PRMTs that catalyze the formation of monomethylated and asymmetrically dimethylated
arginines.
1.5. Protein arginine methyltransferase 1 (PRMT1)
PRMT1 is the predominant type I protein arginine methyltransferase in mammals.
Human PRMT1 gene is located on chromosome 19 (Location: 19q13.3). The protein contains
352 amino acids (AAH19268.2; GI:32425330). There is only one amino acid difference between
human and rat PRMT1, that is, the Tyr161 in hPRMT1 is replaced with His in rPRMT1. Since
His still bears similar aromatic property as Tyr, we can say that PRMT1 is highly conserved
between human and rat species.
The methylation sites in PRMT1 substrates usually fall into RGG or RXR clusters
contained within the Gly and Arg rich (GAR) domains. That means the methylation area is of
multiple positive charges. Zhang and Cheng (30) reported the crystal structure of rPRMT1 bound
with

product

SAH

(S-adenosyl

homocysteine)

and

substrate

peptide

R3

(GGRGGFGGRGGFGGRGGFG). PRMT1 monomer consists of an N-terminus, a SAM binding
domain, a barrel-like domain, and a dimerization arm, with the active site pocket lying between
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the two catalytic core domains (Figure 1.5A). The AdoMet binding domain adopts a rossmann
fold structure that is conserved in other SAM-dependent methyltransferases. SAH is bound in a
deep pocket formed by five parallel β strands. The interactions include the Van der Waals
contacts between G78 and G80 backbone and SAH homocysteine and adenosine ribose, the
bifurcated H-bonds between E100 and the ribose hydroxyl groups, and the H-bond between
E129 and the amino group of adenine. Besides, R45 forms salt bridges between the carboxylate
group of homocysteine and the active site residue E144, and His 45 interacts with one of the
ribose hydroxyl groups through H-bond. The N-terminal helix αX helps to constrain the bound
SAH. The barrel-like domain is special to PRMT family. Several conserved residues between the
two core domains make up the active site, and form a hairpin between strand β4 and helix αD.
Two conserved glutamates - E144 and E153 on this “double-E loop” hydrogen bond the
guanidine group, while the Y148 aromatic ring lies parallel to the hydrophobic methylene groups
of the target arginine (Figure 1.5B). E153Q mutation completely abolished methylation activity,
while E144Q mutation reduced the activity by 3000 fold, indicating that these two negatively
charged glutamates are critical for catalysis. It is proposed that the two invariant glutamates fix
the positive charge on the guanidine group on the δ and one of the ω nitrogens, so that the lone
pair of electrons left on the other ω nitrogen can attack the active methylsulfonium group of
SAM in close proximity. The attacking guanidine nitrogen is deprotonated by a His-Asp relay
system. Therefore the active site pH environment can affect the stability of positively charged
transition state and thus the catalytic effecity. This puts electrostatic and steric requirements for
the residues besides the target arginine.
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A

B

AdoMet binding site

Dimerization Arm

Arg binding site

Rossmann fold domain

C

Beta-barrel domain

Figure 1.5. Strucutres of hPRMT1 and rPRMT1. A. Predicted
structure of hPRMT1 monomer. Structure prediction is made by
Dr. Harrison’s structure and alignment web server based on the
crystal structure of protein 1ORHA and is visualized with
RasMol 2.7.5. The red color indicates the catalytic group Glu153.

The green color indicates the human to rat mutant (Tyr to His) residue, which should be Tyr161
here. B. Reported structure of rPRMT1(E153Q) (PDB/1ORH). Figure made with RasMol 2.7.5.
The bound substrate Arginine and product SAH (Sulfur displaced in spacefill to show its close
proximity with the terminal nitrogen of Arg) are shown in green; The E153Q mutant and H162
are shown in blue. C. Reported active site structure of rPRMT1 with bound Arginine. (30)

PRMT1 functions as dimer or oligomer, as the ∆ARM mutant completely lost catalytic
activity, probably because it is unable to bind SAH properly. The dimer interface is formed
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between the outer surface of Adomet binding domain and the dimerization arm. Acid residues
(20 Asp and Glu) are predominant on the surface of PRMT1, forming several acid grooves which
are supposed to generate an initial binding affinity for positively-charged arg substrates. Surfacescannng mutagenesis study indicated that some of these negatively charged residues were
important for substrate specificity (E47, E129, and E236), substrate binding (E46 and D51),
dimerization/oligomerization, or transcription coactivator function (31). In the crystal structure,
the electron densities of bound peptide substrates were broken into three separate fragments
(Figure 1.6). Other than the arginine bound in the active site, the amino acid residues of the
peptide were not clearly identified due to low resolution of side chain densities. A mixture of
peptide binding modes was proposed from the three disconnected densities. The fact multiple
substrate binding grooves exist on the surface of PRMT1 may explain why PRMT1 methylates
diverse protein substrates. The negatively charged C terminus is close to the active site and may
play an important role for substrate binding or catalysis.

A

B

Figure 1.6. Structure of Ternary Complex of PRMT1-AdoHcy-R3 Peptide. (30) A.
Molecular surface of PRMT1 with bound AdoHcy and Arg. P1, P2, and P3 are three peptide
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binding sites. B. Two side views of A showing the three peptide binding sites and other acidic
grooves.

The crystal structures of PRMT3 and PRMT1 are very similar, with the only difference
(beside N terminus) in β barrel domain - a single residue deletion and an eight-residue insertion;
yet the structure of CARM1 shows significant difference in the β barrel, the helix-turn-helix of
the dimerization arm, and the C-terminal extension which is not present in other PRMTs (32).
The crystal structures of the apo and holo CARM1 catalytic core suggested that SAH binding
induces a structural change forming a substrate binding channel for the access of arginine to the
active site. The N-terminal helices αX and αY, and the first eight residues of the unique Cextension of CARM1 participate in supporting the groove. The central cavity of CARM1 dimer
is much larger than that of PRMT1 or PRMT3 dimer, presumably to accommodate the Cextension. CARM1 with deleted C-extension failed to methylate H3 Arg17. Additionally,
CARM1 possesses a less acidic surface (only five acidic residues). These may be the reasons
why CARM1 methylates a different and smaller substrate profile including histone H3,
p300/CBP and several RNA-binding proteins that lack the highly basic GAR domain or any
consensus motif. But again as high resolusion electron density for a bound peptide in the
complex structure is unavailable, the features and specificity subsites within the substrate
binding groove that can determine the selective recognition of residues flanking the target
arginine haven’t been revealed yet.
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Figure 1.7. Proposed kinetic mechanisms of PRMT1(33)
Several studies of the kinetic mechanism of arginine methylation have been recently
reported. Dr. Thompson’s group suggested that PRMT1 utilizes a rapid equilibrium random
mechanism (RER) for methyl transfer with the formation of dead-end EAP and EBQ complexes
(33). However, Dr. Frankel’s group showed that PRMT6 follows an ordered sequential
mechanism in which SAM binds to the enzyme first and the methylated product is the first to
dissociate (34). The different results in these two studies suggest that kinetics of arginine
methylation can vary slightly among the individual isoforms.
1.6. The study points in this work
1.6.1. The development of fluorescent peptide probes for PRMT1
PRMTs play important roles in normal physiology and human diseases. Simple, rapid,
non-radioactive, colorimetric/fluorescent assays are particularly needed for the enzymatic
study of PRMTs and for the identification of potent PRMT inhibitors. The design of nonradioactive PRMT assays, however, is technically challenging because the substrates and
products of PRMTs exhibited little spectroscopic difference.(35) Recently, several coupled
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colorimetric

and

fluorescent

methods

are

reported

to

study

SAM-dependent

methyltransferases, including PRMTs. In these methods, the enzymatic methylation reaction
is carried out in conjugation with secondary enzymes that convert SAH to adenine and then
hypoxanthine, a spectrometrically active compound,(35) or to homocysteine which is
subsequently detected by thiol-reactive chromogenic/fluorogenic compounds.(36-38) The
major advantage of the coupled methods is that they avoid using radioisotope-labeled
materials and allow for the measurement of PRMT activity via absorption or fluorescent
readouts. However, these methods involve multiple additional components which may
potentially complicate the methylation results. Especially, when used for inhibitor screening,
there is a high chance that the coupling components may be intervened thus leading to
positive hits. Therefore, new alternative methods are highly demanded to serve as research
tools to ecluidate the functions of PRMTs in health and disease as well as to facilitate the
discovery of PRMT inhibitors. Thus we tried to design and evaluate a fluorescent competitive
binding assay of PRMT1 for both basic kinetic analysis and inhibition study. The fluorescent
displacement strategy is particularly useful to probe PRMT-substrate interactions, and thus
finding application in screening organic inhibitors that target the substrate-binding pocket of
PRMTs. Importantly, by applying this method, we elucidated the inhibitory mode of AMI-1, a
potent PRMT inhibitor, the mechanism of which was unknown.
To create the fluorescent reporters that can be used for non-radioactive PRMT binding
assay, we synthesized fluorescein-labeled peptides based on two different substrates of
PRMT1. First, PRMT1 and several other PRMT members are reported to robustly methylate a
number of GAR motifs which frequently occur in RGG repeats of proteins such as fibrillarin
and nucleolin.(23, 39) Herein, we synthesized a fluorescent GAR-rich peptide (R4-FL) which
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contains a fluorescein labeling on a lysine residue. In addition, PRMT1 was previously shown
to methylate histone H4 at the R3 residue.(26, 40, 41) In this case, we used a fluoresceinlabeled H4 peptide, H4-FL,(42) based on the N-terminal 20-aa sequence of histone H4. The
fluorescein group was linked at position 10 through a 2,3-diaminopropionic acid residue
(Dpr). Fluorescein was selected as the reporter group because it has long absorption and
emission wavelengths and its photophysical properties are relatively sensitive to local
microenvironment. We rationalized that fluorescent signals (e.g., intensity, anisotropy)
change accordingly when these small peptide ligands bind to and/or are methylated by
PRMT1, and that when the interaction between PRMT1 and the ligand is disrupted, there is a
recovery of fluorescent signal.
1.6.2. The inhibition study of PRMT1
Given the essential roles that PRMTs play in normal biology and in disease, quite a few
efforts have been invested in developing small molecule PRMT inhibitors both as chemical
genetic tools and as therapeutic agents.(43-45) The first type of chemical inhibitors for PRMTs
are

analogues

of

the

AdoMet

cofactor,

including

S-adenosylhomocysteine

(SAH),

methylthioadenosine, and sinefungin.(44) Due to structural similarities to AdoMet, these
analogue inhibitors target all AdoMet-consuming methyltransferases, such as DNA
methyltransferases, protein lysine methyltransferases, and O-methyltransferases. In the past few
years, several groups reported their work in a row on developing small molecule inhibitors
specific for PRMTs. Most of these studies on PRMT inhibitor discovery adopted targeted or
random screening approaches. The screening strategy is so widely accepted largely because of
technical advancement in computer-aided drug design and in medium- and high-throughput
inhibitor screening. Thus far, the disclosed small molecule PRMT inhibitors include 1 (AMI-
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1),(46) stilbamidine and allantodapsone,(47) the thioglycolic amide RM65,(48) pyrazole amide
compounds,(49) and others.(50-54) It is important to point out that past inhibitor development
efforts were mostly focused on inhibition of the enzyme, presumably, through binding to the
active site. This is also the case with the vast majority of enzyme inhibition work reported related
to other enzymes so far. Because a single PRMT catalyzes the methylation of arginine residues
in multiple proteins, inhibition of a particular PRMT inevitably results in bulky inhibition of
methylations of a large number of proteins, but not on a particular substrate sequence. Herein, we
report a type of compounds that block PRMT1-mediated arginine methylation at micromolar
potency through a unique mechanism. Most of the discovered compounds bear naphthalene and
sulfonate groups and are structurally different from typical PRMT substrates, e.g., histone H4
and glycine- and arginine-rich sequences. To elucidate the molecular basis of inhibition, we
conducted a variety of kinetic and biophysical assays. The combined data reveal that this type of
naphthyl-sulfo (NS) molecules directly targets the substrates but not PRMTs for the observed
inhibition. We also found that suramin effectively inhibited PRMT1 activity. These findings
about novel PRMT inhibitors and their unique inhibition mechanism provide a new way for
chemical regulation of protein arginine methylation.
1.6.3. The transient-state kinetics and catalytic mechanism of PRMT1
Transient state is at the very beginning of a reaction when the enzyme and the substrate is
trying to meet each other and the concentration of reactive E-S complex and the reaction rate are
changing as a function of time. It occurs before steady state when the formation and breakdown
of E-S complex reach an equilibrium and the maximum reaction rate is constant with time.
The functions of PRMTs have been broadly studied in different biological processes and
diseased states, but the molecular basis for arginine methylation is not well defined. Many
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important questions about the PRMT-catalyzed arginine methylation reaction remain to be
answered. For instance, it is not known whether the chemical step or a protein conformational
change in the ES complex is rate-limiting for catalysis. Such a molecular level understanding of
how substrate recognition is coupled to catalysis will be of great significance to evaluate the
function of PRMT activity in different physiological contexts. To address these mechanistic
questions, transient kinetic analyses of arginine methylation are highly desirable. Unfortunately,
such studies are greatly limited by lack of assay tools appropriate for fast measurement of
substrate binding and methylation on rapid time-scales. Here we studied the transient-state
kinetic analysis of PRMT1 catalysis using stopped-flow fluorescence measurement with
fluorescein-labeled peptide substrates. The fast association and dissociation rates suggest that
PRMT1 catalysis of histone H4 methylation follows a rapid equilibrium sequential kinetic
mechanism. The data give direct evidence that the chemistry of methyl transfer is the major ratelimiting step, and that binding of the cofactor SAM or SAH affects the association and
dissociation of H4 with PRMT1. Importantly, from the stopped-flow fluorescence
measurements, we have identified a critical kinetic step suggesting a precatalytic conformational
transition induced by substrate binding. These results provide new insights into the mechanism
of arginine methylation and the rational design of PRMT inhibitors.
1.6.4. The interaction between lysine acetylation and arginine 3 methylation on H4 tail
It has become an increasing recognition that multiple PTM marks at the amino-terminal
tails of the core histones intercommunicate with one another to fundamentally regulate DNA
functions such as transcription, replication, recombination and damage repair (5, 55). At the
molecular level, how individual PTM patterns or codes are created and how they affect
downstream molecular events are poorly defined. More studies are needed to address the
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communicational relationship between functionally related histone modification marks.
Acetylation of H4 at its N-terminal tail is commonly seen in many cell types. With 16 possible
acetylation combinations, cells may benefit by utilizing such combinatorial modification tricks to
fine tune and/or maximize multivalent readouts for diversified functionality. In this study, we
investigated in detail the impact of individual acetylation marks at K5, 8, 12, 16, and their
different combinations on type I and type II methylation at site R3. It was previously shown that
H4 acetylation reduced PRMT1-mediated R3 methylation (40). However, it is not clear how
individual acetylations combinatorially affect R3 methylation and which acetylation site plays a
predominant role in affecting R3 methylation. Furthermore, R3 can be either asymmetrically
dimethylated or symmetrically dimethylated. It remains unknown whether lysine acetylation
affects these two types of methylation in the same or distinct manners. To answer these
mechanistic questions, we created a library of H4 peptides containing all the possible acetylated
isoforms. The concentration of each peptide was calibrated with NMR to obtain the accurate
concentration prior to the enzymatic methylation experiments. Our data reveal that the effect of
lysine acetylation on arginine methylation depends on the site of acetylation and the type of
methylation. While certain acetylations bring a repressive impact on PRMT-1 mediated
methylation, lysine acetylation generally is correlated with enhanced methylation by PRMT5.
Furthermore,

circular

dichroism

study

and

computer

simulation

demonstrate

that

hyperacetylation increases the content of ordered secondary structures at the H4 tail region.
These findings provide new insights into the regulatory mechanism of Arg-3 methylation by H4
acetylation, and unravel that complex intercommunications exist between different PTM marks
in cis. The divergent activities of PRMT1 and PRMT5 with respect to different acetyl-H4
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substrates suggest that type I and type II PRMTs use distinct molecular determinants for
substrate recognition and catalysis.
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CHAPTER 2
INHIBITORY STUDY OF PROTEIN ARGININE METHYLTRANSFERASE 1 USING A
FLUORESCENT APPROACH
(This work is mainly based on the published paper Biochem. Biophys. Res. Commun. 379 (2009)
567-72. In this project, the author is obliged to Dr. Nan Xie, Dr. Jiang Wu, and Chao Yang for
their great contributions to peptide preparation.)
2.1. Introduction
Protein arginine methylation has emerged as an important regulatory mechanism for gene
expression and cellular signalling (18-20). The methylation is catalyzed by protein arginine
methyltransferases (PRMTs) that transfer the methyl group from S-adenosyl-L-methionine
(AdoMet, SAM) to specific arginine residues in histone and nonhistone protein substrates,
resulting in mono and di-methylated arginine residues and S-adenosyl-L-homocysteine
(AdoHcy, SAH). It has been shown that PRMTs are involved in the regulation of diverse
biological processes such as DNA transcription, RNA processing, DNA repair, and cell
differentiation (24, 56-58). As the predominant PRMT protein in mammalian cells, PRMT1
(HRMT1L2) accounts for 85% of cellular PRMT activity (59). Notably, deregulation of PRMT1
has been linked to certain diseases such as breast cancer and leukaemia (60, 61), which suggests
its role as a potential drug target.
Rapid, homogeneous, nonradioactive, and colorimetric or fluorescent assays are
particularly needed for the kinetic analysis of PRMTs and for the identification of potent PRMT
inhibitors. The design of nonradioactive PRMT assays, however, is technically challenging
because the substrates and products of PRMTs exhibited little spectroscopic difference (35).
Recently, several coupled colorimetric and fluorescent methods were reported to study SAM-
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dependent methyltransferases, including PRMTs. In these methods, the enzymatic methylation
reaction is carried out in conjugation with secondary enzymes that convert SAH to adenine and
then hypoxanthine, a spectrometrically active compound (35), or to homocysteine which is
subsequently detected by thiol-reactive chromogenic or fluorogenic compounds (36-38). The
major advantage of the coupled methods is that they avoid using radioisotope-labeled materials
and allow for the measurement of PRMT activity via absorption or fluorescent readouts.
However, these methods involve multiple additional components which may potentially
complicate the methylation results. Especially, when used for inhibitor screening, there is a high
chance that the coupling components may also be inhibited thus leading to false positives.
Therefore, new and alternative methods are highly needed to serve as research tools to ecluidate
the functions of PRMTs in health and disease as well as to facilitate the discovery of PRMT
inhibitors.
In this paper, we report our work of designing peptide-based fluorescent reporters and
using them for biochemical analysis and inhibition study of PRMT1. These fluorescent ligands
are proved to be effective to probe PRMT-substrate interaction with dual modes of fluorescence
intensity and fluorescence anisotropy, thus suited for studying organic inhibitors that target the
substrate-binding pocket of PRMTs. By applying the fluorescent reporters in combination with
radioactive methylation assay, we elucidated the inhibitory mechanism of AMI-1, the first
reported small molecule PRMT inhibitor (46).
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2.2. Results and discussion
2.2.1. Expression and purification of PRMT1
6×His-tagged rat PRMT1 was successfully expressed with BL21(DE3) and purified by
Ni affinity chromatography. As shown in Figure 2.1, a major band of relatively pure PRMT1 was
obtained, which can be used directly in the kinetic study.

1

2

3

4

5

6

7

8

PRMT1

Figure 2.1. SDS-PAGE of rPRMT1 after purification
1. Marker. 2. 70 mM imidazole washing. 3. Beads before elution. 4. 200 mM imidazole
eluant1. 5. 200 mM imidazole eluant2. 6. 200mM imidazole eluant3. 7. 200 mM imidazole
eluant4. 8. Beads after elution.
2.2.2. Design and synthesis of the fluorescent PRMT1 reporters
To create the fluorescent reporters that can be used for nonradioactive PRMT study, we
synthesized fluorescein-labeled peptides based on two different substrates of PRMT1. First,
PRMT1 and several other PRMT members are reported to robustly methylate glycine and

22

arginine-rich (GAR) motifs which frequently occur in RGG repeats of proteins such as fibrillarin
and nucleolin (23, 39). Herein, we made a fluorescent GAR-rich peptide (R4-FL) which is
labeled with fluorescein through a lysine residue (Table 2.1). Apart from methylating GAR
motifs, PRMT1 also methylates histone H4 at the R3 site (26, 40, 41). We synthesized a labeled
H4 peptide, H4-FL (42), by modifying the N-terminal 20-aa sequence of histone H4 with
fluorescein at position 10 through a 2,3-diaminopropionic acid residue (Dpr). Fluorescein was
selected as the reporter group because it has long absorption and emission wavelengths and its
photophysical properties are relatively sensitive to the local microenvironment. We envisioned
that the fluorescent signals (e.g., intensity, anisotropy) of fluorescein might change accordingly
when the peptide ligands bind to and/or are methylated by PRMT1. Synthesis of these peptidyl
compounds was achieved using the Fmoc-based solid phase peptide synthesis protocol.
Table 2.1. Sequences of H4, H4-FL, R4, and R4-FL
Peptide

Sequence

Expected mass Observed mass

H4

Ac-SGRGKGGKGLGKGGAKRHRK

2034.4

2034.1

H4-FL

Ac-SGRGKGGKGDpr(FL)GKGGAKRHRK

2366.7

2366.4

R4

Ac-GGRGGFGGRGGKGGRGGFGGRGGFG

2223.4

2223.2

R4-FL

Ac-GGRGGFGGRGGK(FL)GGRGGFGGRGGFG

2582.4

2581.3

2.2.3. Fluorescence response of the PRMT1 reporters
We first tested whether the fluorescence intensity of fluorescein can change upon ligandenzyme interaction. His6x-tagged recombinant rat PRMT1 was expressed in E. coli and purified
on Nickel-NTA beads. As shown in Figure 2.2, the fluorescence intensity of both H4-FL and R4FL decreases at increasing concentrations of rPRMT1. The magnitude of the change at the
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maximum emission wavelength (524 nm) is approximately 25%. Such a fluorescence intensity
change most likely reflects that the microenvironment surrounding the fluorescein group is
altered after ligand-PRMT1 binding. The molecular factors causing such alteration may include
hydrophobicity variation, prototropic shift, and the presence of new hydrogen bonding with
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Figure 2.2. Fluorescence intensity changes of H4-FL and R4-FL upon interaction
with PRMT1. (a) Emission spectra obtained for H4-FL (0.20 μM) with increasing
concentrations (0, 0.05, 0.10, 0.15, 0.20, and 0.30 μM) of PRMT1. (b) Plot of the fluorescence
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intensity of H4-FL at 524 nm as a function of PRMT1 concentration. (c) Emission spectra
obtained for R4-FL (0.20 μM) with increasing concentrations (0, 0.05, 0.25, 0.84, 1.25, and 2.57
μM) of PRMT1. (d) Plot of the fluorescence intensity of R4-FL at 524 nm as a function of
PRMT1 concentration.

It is an intriguing question whether the reporter molecules can be used to probe the
catalytic process of PRMT1. To investigate this possibility, we mixed R4-FL with PRMT1 in the
presence of AdoMet and monitored the fluorescence emission at 524 nm at different time points.
As shown in Figure 2.3, the fluorescence intensity of R4-FL first decreases rapidly and then
gradually goes up. It is quite likely that the first phase (i.e. the rapid fluorescence decrease)
corresponds to substrate binding and the second phase (i.e. the gradual fluorescence increase)
corresponds to the methyl transfer and/or product release. A detailed stopped flow study will
reveal more information about this complex process. To our knowledge, this is the first example
of reporting a simple fluorescent approach that can be used to examine the pre-steady state
kinetics of PRMT catalysis. Interestingly, the analog inhibitor, sinefungin, is only able to inhibit
the methylation step, suggesting that its inhibition of PRMT1 is not competitive against the
peptide substrate.
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Figure 2.3. Inhibition Effect of Sinefungin on PRMT1 methylation.
B: 0 μM sinefungin, C: 5μM sinefungin, D: 15 μM sinefungin, E: 50 μM sinefungin. 0.4 μM of
PRMT1 is added to the mixed solution of R4-FL (0.2 μM) and Sinefungin (0 μM, 5 μM, 15 μM
or 50 μM). The dropping curve shows the binding of R4-FL and PRMT1, and the raising curve
shows the methylation of R4-FL.

We next examined the fluorescence anisotropy of H4-FL and R4-FL in the presence of
PRMT1. It is expected that, when bound to PRMT1, the molecular mobility of the organic
ligands will be in a more restricted state due to the complex formation, which will give rise to
larger anisotropy readouts. Indeed, our data showed that the fluorescence anisotropy of both H4FL and R4-FL increases as a function of PRMT1 concentration (Figure 2.4). The maximal
magnitudes of the anisotropy enhancement are 100% and 300% for H4-FL and R4-FL,
respectively, which are much larger than that of the fluorescence intensity change. Thus, the
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fluorescence anisotropy or polarization of H4-FL and R4-FL is better suited than fluorescence
intensity for use in screening PRMT1 inhibitors. It should be noted that the dynamic range in
anisotropy could be further increased by using recombinant PRMT1 that contains more bulky
tags such as GST or by reducing the size of the reporter ligands.
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Figure 2.4. Fluorescence anisotropy titration. (a) Fluorescence anisotropy (524 nm) of
H4-FL solution at different PRMT1 concentrations. The concentration of H4-FL is 0.20 μM. The
Kd is calculated to be 0.31 ± 0.04 μM. (b) Fluorescence anisotropy (524 nm) of R4-FL solution
at different PRMT1 concentrations. The concentration of R4-FL is also 0.20 μM. The Kd is
calculated to be 0.40 ± 0.07 μM.

A minor concern is that the added fluorophore might interfere with the interaction of H4
and R4 peptides with PRMT1, thus compromising the methylation reaction. To investigate this
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effect, we measured the steady state kinetic parameters of PRMT1 for both the labeled and nonlabeled peptides. 14C-labeled AdoMet was used as the methyl donor in the assay. The methylated
products were loaded onto P81 paper and quantified by scintillation counting. As shown in Table
2.2, the Km of H4-FL and R4-FL, respectively, doubled that of H4 and R4, while the kcat values
decreased by half. The largest effect was only a 3-4 fold difference in the specificity constants
(V/K). The comparisons of these kinetic parameters suggest that the attached fluorescein group
moderately affects the methylation of the peptide substrates by PRMT1, and overall, these
labeled ligands are still reasonably good substrates of PRMT1.

Table 2.2. Steady state kinetic parameters of rPRMT1 in the methylation of H4, R4
and their fluorescent derivatives. The concentration of PRMT1 and AdoMet is 0.01 μM and 30
μM, respectively.
substrate

Km, μM

kcat, min-1

kcat/Km, min-1μM -1

H4

0.64 ± 0.04

0.81 ± 0.01

1.27 ± 0.08

H4-FL

1.14 ± 0.13

0.43 ± 0.01

0.38 ± 0.04

R4

0.90 ± 0.06

0.69 ± 0.01

0.77 ± 0.05

R4-FL

1.84 ± 0.56

0.45 ± 0.05

0.24 ± 0.08

2.2.4. Inhibitory study of AMI-1 using the fluorescent strategy
After having assessed the fluorescent responses of H4-FL and R4-FL upon interaction
with PRMT1, we applied the reporters to probe the interaction of PRMT1 with AMI-1, the first
reported small-molecule PRMT inhibitor that was discovered by Bedford and co-workers.(46)
AMI-1 inhibits several PRMTs (PRMT1,-3,-4,-6 and Hmt1p) and bears no similarity to AdoMet
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analogues. The mechanism by which AMI-1 inhibits the enzymatic activity of PRMTs is still not
identified. Due to certain structural similarity to peptidyl arginine, it was speculated that AMI-1
may bind to the substrate-binding pocket of the PRMT enzymes (46), but a recent docking study
suggested that AMI-1 might interact with residues of the AdoMet binding pocket (48). To
elucidate the inhibitory mode of AMI-1, we examined the interaction of AMI-1 with PRMT1
using our fluorescent reporters. As shown in Figure 2.5, the fluorescence anisotropy of both H4FL/PRMT1 and R4-FL/PRMT1 mixtures decreases at increasing concentrations of AMI-1,
indicating that the fluorescent ligands are displaced from binding to PRMT1 by the inhibitor.
The inhibition constant (Ki) of AMI-1 in these two competitive assays is calculated to be 15.8 ±
3.5 μM and 19.8 ± 3.1 μM, respectively, using the method of Nikolovska-Coleska, et al.(64)
This evidence demonstrates that AMI-1 targets the same binding pocket in PRMT1 with the H4
and R4 substrates. It also suggests that histone H4 and RGG-rich substrates may bind to PRMT1
in a similar structural manner.
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Figure 2.5. Competitive inhibition assays of AMI-1 against H4-FL (a) and R4-FL (b)
using the mode of fluorescence anisotropy. The reporter and PRMT1 concentration is 2.00 μM
and 4.00 μM for H4-FL assays and 0.20 μM and 2.00 μM for R4-FL assay.

To further substantiate the inhibitory mode of AMI-1, we investigated the inhibition
pattern of AMI-1 versus AdoMet and the peptide substrates using radioisotopic assay. Initial
velocities of PRMT1 were determined, and the data were plotted in double-reciprocal form with
E/velocity versus 1/[H4], 1/[R4], and 1/[AdoMet], respectively, at several fixed concentrations
of AMI-1 (Figure 2.6). The results show that AMI-1 is a linear competitive inhibitor versus H4
(and also R4, data not shown), while is noncompetitive (mixed type) versus AdoMet. The Ki of
AMI-1 from the competitive kinetic assay (Figure 2.6a) is calculated to be 17.7 μM, which is
consistent with the results obtained from the fluorescence anisotropy competitive binding
measurement. These data indicate that AMI-1 competes with the protein/peptide substrate, but
not AdoMet, for the same form of PRMT1 and the same mutually exclusive binding site, thus
further validating the conclusion that AMI-1 inhibits the methylase activity of PRMT1 by
blocking the access of protein/peptide substrates.
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a

b

Figure 2.6. Inhibition pattern analysis of AMI-1 to PRMT1 plotted as reciprocal
plots. a. E/V versus 1/[H4] at fixed AdoMet (5 μM) and varying AMI-1: 0 μM (♦), 50 μM ( ),
100 μM ( ), and 200 μM (x). The inhibition plot of AMI-1 against R4 was similar to that of H4
and is not shown. b. E/V versus 1/[AdoMet] at fixed H4 (2 μM) and varying AMI-1: 0 μM (♦),
50 μM ( ), and 100 μM ( ).
There are several valuable merits about the fluorescent competitive binding assay
developed herein. First, it is simple, thus avoiding complications caused by using coupling
components. Second, this displacement strategy is geared to target compounds that block PRMTsubstrate interaction, which is directly associated with methylase activity. Since GAR motifcontaining sequence is a known common feature of substrates for many PRMTs,(23) R4-FL is
not only a fluorescent reporter of PRMT1, but will be applicable to other PRMT members as
well. Third, since the assay is independent of the enzymatic activity, the strength of the
methylase activity of PRMTs does not directly influence the assay. This catalytic activity-
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independent feature is particularly important for PRMTs since many recombinant PRMT
enzymes exhibited very weak methylase activities, so that it is difficult to characterize the PRMT
enzymatic reaction in a practical manner. For example, recombinant mouse PRMT4/CARM1
also methylates a RGG-repeat sequence,(65) but its activity is so low that no adequate readable
signals would be produced using a coupled assay method within regular assay time frame
(usually less than one hour). Therefore, although the fluorescence anisotropy/intensity
measurement is not a direct detection of PRMT enzymatic activity, our strategy complements
and offers unique advantages over the current PRMT assay toolkits, and will be particularly
useful to study and screen potent PRMT inhibitors.

2.3. Conclusion
We demonstrated the use of single fluorophore-labeled reporters to examine the substrate
binding and methylase activity of PRMT1. This method will be of wide application in studying
protein-substrate interactions and in screening PRMT inhibitors. By combining the fluorescent
assay with radioactive measurement, we established the inhibitory mechanism of AMI-1; i.e., it
inhibits the enzymatic activity of PRMT1 by dislodging protein/peptide substrates out of the
binding pocket in the enzyme. Furthermore, we showed that the fluorescence intensity of R4-FL
is sensitive to the progression of both substrate binding and methylation, suggesting that it will
be a useful fluorescent probe to investigate the transient kinetic mechanism of PRMT catalysis.
2.4. Experimental
2.4.1. Synthesis of the fluorescent reporters.
Solid Phase peptide synthesis (SPPS) was performed on a PS3 peptide synthesizer
(Protein Technologies) using the Fmoc (N-(9-fluorenyl) methoxycarbonyl) strategy. Fmoc-
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protected amino acids, Rink amide resin and Pre-loaded Wang resin were purchased from
NovaBiochem. All the synthetic reactions were performed at room temperature unless indicated
otherwise. Removal of Fmoc was performed with 20 % v/v piperidine/DMF. For the coupling of
each amino acid (AA), 4 eq. of AA/HBTU/HOBt (N-Hydroxybenzotriazole) were used. Nmethylmorpholine (NMM) was used as the catalytic base. The N-terminal amino group was
acetylated with Ac2O unless indicated otherwise. The Dde (dimethyldioxocyclohexylidene)
group on the lysine residue was removed with a solution of 2% hydrazine in DMF (66), and then
the free amino group reacted with fluorescein-OSu for fluorophore labeling. After solid phase
synthesis, the resins were subsequently washed with DMF, dichloromethane and then dried in
vacuum for at least 2h before cleavage. Peptides were cleaved from resin by treatment with 95%
TFA, 2.5% H2O and 2.5 % triisopropylsilane (handling of TFA must be performed in a secure
hood) for 3-4h. Cold ether was used to precipitate the products. Crude products were collected
by centrifugation and were washed with cold diethyl ether. After lyophilization, the compounds
were re-dissolved in water and purified with reverse-phased (RP) HPLC (C18, Varian) on a
Varian Prostar HPLC system using linear gradients of H2O/0.05% TFA (solvent A) vs.
acetonitrile/0.05% TFA (solvent B). Analytical HPLC and MALDI-MS were used for
characterization.
2.4.2. Enzymatic methylation assay.
Recombinant His6x-tagged rat PRMT1 enzyme was expressed using a pET28b vector in
E. coli and purified on nickel-NTA beads. The methylation buffer contained 50 mM HEPES (pH
= 8.0), 0.5 mM DTT, 1 mM EDTA, and 50 mM NaCl. Methylation assays of H4 and R4 were
carried out in 0.5 mL plastic tubes at 30°C with a reaction volume of 30 μL. To measure the
kinetic parameters, the concentration was 10 nM for PRMT1 enzyme and 30 μM for 14C-AdoMet
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(GE Healthcare), and the concentration of peptide ranged from 0 to 20 μM. Reactions were
initiated with PRMT1 after the other components were incubated at 30°C for 5 min. The reaction
was quenched by loading the mixtures onto the surface of a P81 filter paper disc. After washing
and drying the paper, the amount of product was quantified by liquid scintillation. The inhibition
pattern analysis of AMI-1 was determined by measuring initial velcotities of PRMT1 at different
concentrations of one substrate, a fixed concentration of the second substrate, and selected
concentrations of AMI-1. The data were displayed in double reciprocal format and fitted to
competitive or noncompetitive kinetic equations (67).
2.4.3. Fluorescence assay
The fluorescence intensity and anisotropy were measured using a Fluoro-Max 4
fluorimeter (Horiba Jobin Yvon). The buffer was the same as that of the radioactive assay. A 450
μL reaction mixture with 0.2 μM H4-FL or R4-FL was made in a 0.5 mL plastic tube and
incubated at 30 °C in the chamber for 5 min. Then increasing amount of PRMT1 was added
while keeping the reporter concentration constant. The fluorescence spectra of each sample were
taken and the temperature of the sample chamber was maintained at 30 °C throughout the
measurement. The excitation wavelength was chosen at 498 nm, the emission wavelength ranged
from 500 nm to 650 nm, and the excitation and emission slit widths were both set at 2 nm. The
wavelength of maximum emission was found to be 524 nm for both fluorescein-labeled peptides.
The maximum fluorescence intensity data at 524 nm was extracted and plotted as a function of
PRMT1 concentration. For the kinetic fluorescent methylation analysis of R4-FL by PRMT1 and
the effect of sinefungin, a mixture containing 0.2 μM R4-FL, 15 μM AdoMet and varied
concentrations of sinefungin (0 μM, 5 μM, 15 μM, and 50 μM) was prepared and incubated at 30
°C for 5 min, then, 0.4 μM of PRMT1 was added and fluorescence intensity was monitored at
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different time points. The kinetic curves were normalized to the same starting point for
comparison. Fluorescence anisotropy was tested under similar conditions as described above.
The excitation wavelength was fixed at 498 nm and the emission wavelength was selected as 524
nm (slit 2, 2 nm). Fluorescence anisotropy at 524 nm was acquired at different concentrations of
PRMT1 and the data were fitted to a quadratic equation as a function of PRMT1 concentration.
The inhibition effect of AMI-1 was analyzed using fluorescence anisotropy titration in similar
conditions. For H4-FL assay, the peptide and PRMT1 concentrations were fixed at 2 μM and 4
μM respectively; For R4-FL assay, they were fixed at 0.2 μM and 2 μM respectively. Increasing
concentrations of AMI-1 were added for both assays until saturation was reached.
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CHAPTER 3
DISCOVERY AND MECHANISTIC STUDY OF A CLASS OF PROTEIN ARGININE
METHYLATION INHIBITORS
(This work is mainly based on the published paper, J. Med. Chem. 53 (2010)6028-39. In this
project, the author is obliged to Dr. Mingyong Li and Dr. Binghe Wang for their great
contributions to inhibitor virtual screening.)
3.1. Introduction
Among different post-translational modifications, arginine methylation is catalyzed by
protein arginine methyltransferases (PRMTs), which utilize the cofactor S-adenosyl-Lmethionine (AdoMet, SAM) as a methyl donor. Thus far, eleven PRMT members have been
identified and are categorized into two major types, type I and type II, according to the substrate
and product specificity.(18-20) Type I enzymes (e.g., PRMT-1, -2, -3, -4, -6, and -8) catalyze the
transfer of the methyl group from AdoMet to one of the terminal nitrogen atoms of the guanidino
group of specific arginine residues in a protein substrate, resulting in ω-NG-monomethylarginine
(MMA, L-NMMA) and ω-NG,NG-asymmetric dimethylarginine (ADMA) products.(19, 21-24)
Type II enzymes (e.g., PRMT 5, 7, and 9) catalyze the formation of MMA and ω-NG, N’Gsymmetric dimethylarginines (SDMA).(24-27) The catalytic properties of PRMT-10, and -11
remain to be characterized. Protein arginine methylation is involved in a broad spectrum of
biological processes, including transcriptional activation and repression, mRNA splicing,
nuclear─cytoplasmic shuttling, DNA repair, and signal transduction.(29)
In recent years, the significance of PRMTs in human diseases is being increasingly
recognized. As the predominant PRMT member, PRMT1 is likely to be responsible for bulk
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protein arginine methylation in mammalian cells. Aberrant expression of spliced forms of
PRMT1 has been observed in several tumor states, including breast cancer(61, 68) and colon
cancer.(69, 70) Deregulation of the methylation of histone H4 at R3 (a major cellular substrate of
PRMT1) is a suggestive marker of prostate cancer.(71) PRMT1 was recently shown to be a
component of Mixed Lineage leukemia (MLL) transcription complex and the activity of PRMT1
is required for malignant transformation.(60) PRMT4 (better known as CARM1) is
overexpressed in both aggressive prostate cancer and breast tumor.(72, 73) The type-II PRMT
member, PRMT5, is recruited to the promoters of tumor suppressor genes such as ST7 and
NM23, and its overexpression was observed in a variety of lymphoma and leukemia cells,(18,
74) in gastric carcinoma,(75) and in immortalized fibroblast cells.(76) In cardiovascular
disorders, PRMT activity is associated with the up-regulation of serum ADMA, which
subsequently blocks NO production and causes many cardiovascular implications such as
diabetes and hypertension.(77-79) Furthermore, a number of viral proteins have been shown to
be substrates of PRMTs, such as the herpes simplex virus 1 nuclear regulatory protein ICP27, the
hepatitis C virus protein NS3, the Epstein-Barr virus nuclear antigen 2, adenovirus E1BAP5 and
L4-100K, and the HIV-1 proteins Rev, Tat, and the nucleocapsid protein.(23, 29) Together, these
multiple lines of evidence point toward the extensive roles of PRMTs in human pathogenesis and
suggest that PRMT inhibitors could be very useful research tools and be of pharmacological
merits for disease intervention.
Given the essential roles that PRMTs play in normal biology and in disease, quite a few
efforts have been invested in developing small molecule PRMT inhibitors both as chemical
genetic tools and as therapeutic agents.(43-45) The first type of chemical inhibitors for PRMTs
are

analogues

of

the

AdoMet

cofactor,

including

S-adenosylhomocysteine

(SAH),
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methylthioadenosine, and sinefungin.(44) Due to structural similarities to AdoMet, these
analogue inhibitors target all AdoMet-consuming methyltransferases, such as DNA
methyltransferases, protein lysine methyltransferases, and O-methyltransferases. In the past few
years, several groups reported their work in a row on developing small molecule inhibitors
specific for PRMTs. Most of these studies on PRMT inhibitor discovery adopted targeted or
random screening approaches. The screening strategy is so widely accepted largely because of
technical advancement in computer-aided drug design and in medium- and high-throughput
inhibitor screening. Thus far, the disclosed small molecule PRMT inhibitors include 1 (AMI1),(46) stilbamidine and allantodapsone,(47) the thioglycolic amide RM65,(48) pyrazole amide
compounds,(49) and others.(50-54) It is important to point out that past inhibitor development
efforts were mostly focused on inhibition of the enzyme, presumably, through binding to the
active site. This is also the case with the vast majority of enzyme inhibition work reported related
to other enzymes so far. Because a single PRMT catalyzes the methylation of arginine residues
in multiple proteins, inhibition of a particular PRMT inevitably results in bulky inhibition of
methylations of a large number of proteins, but not on a particular substrate sequence. Herein we
report our discovery of a class of inhibitors that modulate PRMT-mediated reaction through
binding to the substrates, thus revealing a new way of chemical modulation of PRMT activities.
3.2. Results and discussion
3.2.1. Screening for new PRMT1 inhibitors
In an effort to discover potent and selective PRMT1 inhibitors, we conducted a virtual
screening to search for novel PRMT1 inhibitors from the ChemBridge small molecule compound
collection (about 0.4 million compounds) using the reported crystal structure of rat PRMT1.(80)
Briefly, the 2D structures of individual compounds were first converted into 3D structures by
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using the CONCORD program(81) and then docked to the PRMT1 structure (PDB entry: 1OR8)
using DOCK 6 program.(82) From this virtual screening, fifty compounds with high consensus
scores were selected and experimentally tested for PRMT1 inhibition (see Table SI-1 in the
supplementary information). In a typical radioactive experimental assay, a reaction mixture
contained 0.1 μM of recombinant His6x-PRMT1, 5 μM of [14C]-labeled AdoMet, and 2 μM of
the amino-terminal tail peptide of histone H4, i.e., H4(1-20), as the substrate, and was incubated
at 30°C in the presence or absence of 100 μM of individual compounds. The retained fractional
activity of PRMT1 was used as a parameter to evaluate the potency of the compounds in
blocking PRMT1-mediated methylation. It is notable to mention that, for all the enzymatic
assays, the methylation reaction is maintained under initial condition so that the reaction yields
of the limiting substrates are lower than 10%, which is to ensure that the concentrations of
AdoMet and peptide substrate do not decrease significantly over the time course of methylation
reaction. The experimental assays, unfortunately, showed that the accuracy of the virtual
screening was rather poor. Out of the fifty tested compounds, only one weak hit, 2 (#5252870,
ChemBridge product ID), was found to show inhibition potency at IC50 about 1 mM.
Subsequently, we searched for structural analogues of 2 from the ChemBridge small molecule
collection to examine if more potent inhibitors can be found. Thirty-one compounds that bear
similar structures or functional groups with 2 were selected and radioactive methylation assays
were performed to evaluate this second set of compounds for inhibition of PRMT1 (Figure 3.1
and Figure SI-1). From the test, nine compounds were identified to have inhibition activity
against PRMT1 and their IC50 values ranged from 12 to 867 μM (Table 3.1). Interestingly, we
noticed that some of the tested inhibitors bear great structural similarity to 1, a previously
reported PRMT1 inhibitor by Bedford’s group.(46) All these compounds have rigid, planar,
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conjugated systems, and contain one or more naphthalene aromatic rings. It is also recognized
that most of them have negatively charged sulfonate groups and polar hydroxyl groups. Herein,
we name these compounds as 3 (NS-1), 4 (NS-2), 5 (NS-3) and so on because of their
characteristics of possessing naphthalene and sulfo groups. We also compared the inhibition
potencies of these inhibitors with several PRMT1 inhibitors recently reported in the literature,
including 1, stilbamidine and allantodapsone. As shown in Table 3.1, stilbamidine (IC50 = 105.7
μM) exhibited comparable inhibition activity with 1 (IC50 = 137.1 μM). The inhibition potency
of the other PRMT1 inhibitors, including allantodapsone, and compound 5756663 and 7280948
reported in the literature,(47, 50) is even weaker. For example, at 2 mM of these three
compounds, still 45%, 87%, and 100% of PRMT1 activity retains, respectively. By contrast, the
NS-series of compounds identified here are quite stronger PRMT1 inhibitors. Four of these
inhibitors, i.e., 3, 4, 5, and 6 (NS-4), showed stronger potency than 1 and stilbamidine. In
particular, 3 exhibited the best inhibition potency with an IC50 of 12.7 μM, which is about tenfold lower than that of 1 and stilbamidine under the same reaction condition.
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Figure 3.1. Structures of selected PRMT1 inhibitors
Table 3.1. Inhibition of PRMT1 by selected compounds.
IC50 values of different NS compounds were tested in the radioactive inhibition assays with 2
μM of H4(1-20) or R4, 5 μM of [14C]-AdoMet, 0.1 μM of PRMT1, and increasing
concentrations of each inhibitor.

Compounds

IC50 (μM) for H4(1-20)
methylation

IC50 (μM) for R4
methylation

3

12.7 ± 0.1

741.7 ± 75.0

4

43.1 ± 1.0

108.4 ± 8.4

5

72.1 ± 1.0

463.1 ± 99.2

6

104.2 ± 3.9

227.8 ± 7.8

7

205.9 ± 25.2

1200 ± 16

8

234.1 ± 10.1

595.8 ± 37.5

9

280.6 ± 27.1

No inhibition at 2 mM
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10

325.0 ± 36.9

No inhibition at 2 mM

11

867.4 ± 13.6

No inhibition at 2 mM

stilbamidine

105.7 ± 0.7

1150 ± 33

1

137.1 ± 12.1

375.6 ± 7.8

suramin

5.33 ± 0.23

1011 ± 20

3.2.2. The kinetic pattern of PRMT1 inhibition by 3.
To provide the biochemical basis of PRMT inhibition by this type of NS compounds, we
investigated the inhibition mechanism of 3, the most potent inhibitor in the series. First, we
performed a fluorescence anisotropy binding assay to check if the inhibitor can compete with the
PRMT1 substrates. In this experiment, a fluorescein-labeled amino-terminal H4 peptide, namely
H4(1-20)FL, with the sequence of Ac-SGRGKGGKGDpr(FL)GKGGAKRHRK, was used as a
substrate ligand for PRMT1 binding.(83) The anisotropy of H4(1-20)FL increased upon binding
to PRMT1, due to formation of a large macromolecular PRMT1-ligand complex (Figure 3.2). A
Kd value of 0.49 ± 0.10 μM was calculated. Addition of 3 led to reversal of the anisotropy
change, thus offering direct evidence that 3 is a competitive inhibitor versus the peptide
substrate. Ki of 3 was deduced to be 1.71 ± 0.54 μM by fitting the titration data using the
DynaFit program.(84) Similar competitive binding between 3 and a fluorescently labeled
glycine- and arginine-rich (GAR) substrate, R4FL was also observed (Figure SI-2). To further
validate the results of competitive inhibition, we conducted steady-state kinetic characterization.
The initial velocities of PRMT1 were measured at several selected concentrations of the inhibitor
over a range of varied concentrations of one substrate while fixing the concentration of the other.
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The data were plotted in the double reciprocal fromat with 1/velocity versus 1/(concentration of
the varied substrate) (Figure 3.3). The kinetic inhibition data points were analyzed by fitting to
the linear competitive or noncompetitive inhibition equations.(67) As can be seen from the
double-reciprocal plots, a series of straight lines intersected on the 1/velocity ordinate when the
concentrations of H4(1-20) are varied, while the intersecting point moved to the western side of
the ordinate when concentrations of AdoMet are varied. These data clearly demonstrate that 3 is
competitive versus the peptide substrate and noncompetitive versus the methyl donor. This result
is consistent with the fluorescent binding assay, and is also in agreement with our previous report
showing that 1 is competitive versus peptide substrates and noncompetitive versus AdoMet.(83)
In addition, 6, another inhibitor in this class, also exhibited the same inhibition pattern (Figure
SI-3 and Figure SI-4b). These combined results support that this type of naphthalene-sulfo
derivatives target PRMT1 by blocking the access of the substrate to the PRMT1 active site.
Interestingly, the positively charged stilbamidine also showed competitive binding pattern in
respect to the peptide substrate (Figure SI-4a), which is consistent with a previous report.(47)
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Figure 3.2. Competitive binding measurement with fluorescence anisotropy. (a)
Fluorescence anisotropy of H4(1-20)FL at different concentrations of PRMT1. The
concentration of H4(1-20)FL was fixed at 0.2 μM. Kd of H4(1-20)FL to PRMT1 was calculated
to be 0.49 ± 0.10 μM. (b) Fluorescence anisotropy (524 nm) of H4(1-20)FL and PRMT1
complex at different concentrations of 3. The concentrations of H4(1-20)FL and PRMT1 were
kept constant at 0.2 μM and 2.0 μM, respectively. Ki of 3 was calculated to be 1.71 ± 0.54 μM
by fitting the titration data with DynaFit program.
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Figure 3.3. Kinetic analysis of PRMT1 inhibition by 3. a. Double-reciprocal plotting of
initial velocities versus varied concentrations of H4(1-20). The concentration of [14C]-AdoMet
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and 20 μM(●). b. Double-reciprocal plotting of initial velocities versus varied concentrations of
[14C]-AdoMet. The concentration of H4(1-20) was fixed at (2 μM) and the concentration of 3
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was selected at 0 μM (♦), 5 μM (■) and 10 μM (▲). 0.03 μM of His6x-rPRMT1 was used in all
these assays.

3.2.3. Selectivity of 3.
It is of interest to examine whether the NS inhibitors target PRMT1 selectively or also
inhibit other PRMT members. Using radioactive methylation assays, we measured inhibitory
activities of 3, the most potent compound in this series, towards PRMT3, PRMT4/CARM1, and
PRMT6 (Table 3.2). The inhibition potency of 3 for GST-tagged hPRMT1 is similar to that for
His6x-rPRMT1, with an IC50 of 12.9 ± 0.2 μM. PRMT3 was inhibited at a lower IC50 of 7.1 μM.
At the concentration of 500 μM, 3 showed no apparent inhibitory effect to CARM1 (5μM of
CARM1, 1 mM of H3(1-31), 30 μM of SAM). The IC50 for PRMT6 is about three-fold larger
than that for PRMT1. It is worth mentioning that PRMT1 and PRMT3 share similar substrate
specificity both of which methylate H4 and GAR peptides. On the other hand, CARM1 exhibits
distinct substrate specificity from PRMT1. CARM1 targets H3 but does not methylate GAR
sequences.(23) Therefore, the variation in inhibition potency is likely caused either by the
differences between CARM1 and PRMT1 structures, or by the distinct nature of the substrates
used. Overall, 3 inhibits PRMT1 and PRMT3 stronger than CARM1 and PRMT6.
Table 3.2. Comparison of the inhibition of PRMT-1, -3, -4, and -6 by Compound 3.
Data obtained from the results of the radioactive methylation assays. For the inhibition of His6xrPRMT1 or GST-hPRMT1, 2 μM of H4(1-20), 5 μM of [14C]-SAM and 0.1 μM of enzyme were
used. For the inhibition of His6x-PRMT3, 2 μM of R4, 5 μM of [14C]-SAM and 0.1 μM of
enzyme were used. For the inhibition of GST-CARM1, 1 mM of H3(1-31), 30 μM of [14C]-SAM
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and 5 μM of enzyme were used. For the inhibition of His6x-PRMT6, 10 μM of H3(1-31), 5 μM
of [14C]-SAM and 0.5 μM of enzyme were used.

Peptide substrate and its Km (μM)

IC50 (μM) of 3

His6x-rPRMT1

H4(1-20); 0.64 ± 0.04

12.7 ± 0.1

GST-hPRMT1

H4(1-20); 0.69 ± 0.04

12.9 ± 0.2

His6x-PRMT3

R4;0.92 ± 0.15

7.1 ± 0.2

GST-CARM1

H3(1-31); 796 ± 204

~ 2 mM

His6x-PRMT6

H3(1-31); 9.1 ± 1.2

39.2 ± 2.8

3.2.4. 3 directly targets the substrates, but not PRMT1.
One paradox question is that the NS-series of inhibitors bear none or little structural
similarity to the arginine-containing substrates of PRMT1 such as histone H4 or GAR peptides.
In particular, all the reported PRMT1 substrates are rich in positive residues, i.e., arginines
and/or lysines. The crystal structure of PRMT1 also reveals several large acidic grooves present
at the protein surface which have been proposed to participate in the recognition of
substrates.(80) On the other hand, most of the NS compounds are negatively charged due to the
existence of one or more sulfonate groups. Therefore, it seems difficult to envision that 3 and its
analogues will bind to PRMT1 at the same site as that of substrates in order to explain the
competitive nature between the inhibitor and the peptide substrates. To look into these paradox
problems, we hypothesized that 3 and its analogue inhibitors might bind to the PRMT1 substrate
directly and that the binding subsequently prevents the substrate from accessing to PRMT1.
Under this scenario, inhibitor-substrate interaction is likely facilitated by the electrostatic
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interaction between the negatively-charged sulfonate groups and the cationic arginine guanidino
group, as well as the van der Waals interaction between the naphthalene ring and the
hydrophobic side chains in the substrate. It is conceivable that such interaction may shield the
key motifs in the substrate so that they are not recognized by enzyme. To nail down the
mechanistic details, we conducted several biophysical measurements to detect inhibitor-substrate
and inhibitor-enzyme association.
The interaction between the inhibitors and the PRMT1 substrate was confirmed by
several experiments. First, when mixing high concentrations of H4(1-20) and 3 or 1 (e.g., 100
μM of peptide and 200 μM of inhibitor), a red or brown precipitate occurred immediately. We
reasoned that the precipitation is a strong indication of the association between H4 substrate and
the inhibitors. The precipitate was pelleted by centrifugation, washed with water, dissolved in
5% TFA, and analyzed with MALDI-MS. Indeed, the mass spectra revealed a peak
corresponding to H4(1-20)—1 complex (Figure 3.4). We could not observe a peak for the H4(120)—3 complex on MS spectra, probably due to the instability of H4(1-20)—3 and/or the strong
anionic nature of 3.
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Figure 3.4. Association of 1 with H4(1-20) peptide detected by MALDI-MS. 100 μM
of H4(1-20) and 200 μM of 1 were mixed in the reaction buffer. The precipitate formed was
pelleted by centrifugation, washed with H2O, dissolved in 5% TFA, and analyzed by MALDIMS.

Next, we examined UV-Vis spectra of 3 in the presence of different concentrations of
H4(1-20) or PRMT1 (Figure 3.5). 3 has a maximum absorption at 498 nm with extinction
coefficient of 0.0182 μM-1cm-1. When H4(1-20) was gradually added to a solution of 3 (3
concentration was kept constant at 40 μM), the absorbance decreased dramatically. For instance,
at 10 μM of H4(1-20), the absorbance at 498 nm decreased to 25% of the original value. By
contrast, the presence of PRMT1 had a quite minor effect on the absorption of 3. At 10 μM of
PRMT1, the absorbance of 3 at 498 nm still retained 83%. These data directly pointed out that
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the interaction between 3 and H4(1-20) is much stronger than 3—PRMT1 interaction, if there is
any.
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Figure 3.5. UV-Vis spectral change of 3 upon the addition of H4(1-20) or His6xPRMT1. 40 μM of 3 was titrated with 0 μM (red), 5 μM (blue) and 10 μM (green) of H4(1-20)
(a) or PRMT1 (b).

We then measured the fluorescence emission of H4(1-20)FL in the presence of 3. Since
the absorption band of 3 overlaps with the fluorescence emission peak of H4(1-20)FL, it is
anticipated that fluorescence energy transfer from fluorescein (donor) to 3 (acceptor) will occur
if the two molecules form a complex. Indeed, addition of the inhibitor quenched the fluorescence
emission of H4(1-20)FL (Figure 3.6). On the other hand, in the control experiment, addition of
the inhibitor to a fluorescein solution caused little change to its fluorescence spectra (after
removing the inner filter effect). These data demonstrate that the interaction between the
inhibitor and H4(1-20)FL depends on the H4 peptide itself, instead of being caused by the

49

attached fluorescein label. The Kd of 3 from the fluorescence binding measurement is 2.53 ± 0.64
μM, which is in the similar range as the value measured from the fluorescence anisotropy
titration. Furthermore, we determined the binding stoichiometry of 3 with H4(1-20)FL by using
the Job’s method (Figure 3.7). The intersecting point appears at 0.5 in the plot, suggesting that 3
binds to H4(1-20)FL at 1:1 ratio.

Figure 3.6. Impact of 3 on the fluorescence spectra of H4(1-20)FL. a. Fluorescence
emission spectra of H4(1-20)FL (0.2 μM) at different concentrations of 3 (0 ~ 28.2 μM).
Excitation wavelength was 498 nm. Fluorescence spectrum change of NHS-fluorescein (0.2 μM)
upon titration with 3 was also measured as a control (Spectra not shown). b. Fluorescence
intensity of H4(1-20)FL at 524 nm as a function of 3 concentration (after removing the inner
filter effect). Inlet: Fluorescence intensity of NHS-fluorescein at 524 nm as a function of 3
concentration (after correction).
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Figure 3.7. Determination of the binding stoichiometry of 3─H4(1-20)FL complex
by Job’s Method. The ratio of 3/H4(1-20)FL was varied while the total concentration of H4(120)FL and 3 was fixed at 0.5 μM. The fluorescence intensity (524 nm) of each solution was
measured and normalized, and plotted as a function of the molar fraction of 3.

We also attempted to study 3—H4(1-20) interaction using circular dichroism (CD)
spectra. In the spectra, H4(1-20) showed a pattern of absorption that is correspondent with
random coil structures (Figure 3.8). Upon addition of 3, the absorption band for the random coil
decreased, indicating that the inhibitor caused a structural change to H4 peptide. However, upon
continuous addition of 3, a red precipitate occurred which prevented further accurate quantitative
analysis of H4(1-20)—inhibitor interaction. Similar results were also observed for the interaction
between 1 and H4(1-20) (data not shown).
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Figure 3.8. CD study of H4(1-20) association with 3. 100 μM of H4(1-20) was titrated
with 0 μM (∆), 100 μM (♦), and 200 μM (●) of 3 in 10 mM of Tris buffer (pH 7.4). CD
spectrum change of H4(1-20) was monitored.

In enzyme inhibition, if an inhibitor targets the active site of an enzyme, its inhibition
potency will be largely determined by the binding affinity between the inhibitor and the enzyme,
with little interference by substrates. In our case, however, the experimental findings show that
NS compounds target the substrate, but not the enzyme. This suggests that the potency of these
inhibitors in blocking PRMT1 activity will be greatly affected by the nature of the substrate used
for the assay. To investigate whether this is true, we tested PRMT1-mediated methylation on
H4(1-11) and the inhibition by 3. Indeed, 3 inhibited the methylation of H4(1-11) with an IC50
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(i.e., 176.5 μM) significantly higher than that of H4(1-20) methylation (i.e., 12.7 μM). These
data indicate that the inhibition caused by the NS molecules depends on the structural sequences
of the substrates used, and strongly validate the proposal that these inhibitors target substrate,
instead of enzyme. On the other hand, stilbamidine inhibited the methylation of H4(1-20) and
H4(1-11) with similar Ki, i.e., 25.6 μM and 35.0 μM, respectively. Therefore, the inhibition
mode of stilbamidine is different from that of NS compounds. Our data, in agreement with a
previous study,(47) support that stilbamidine targets the active site of PRMT1 to compete with
substrates.
By now, there is no structural information available regarding the nature of H4(1-20)—3
interaction. The potency difference of 3 in inhibiting H4(1-20) methylation versus H4(1-11)
methylation suggests that the inhibitor targets both the N-terminal and C-terminal residues in
H4(1-20). The 1:1 stoichiometry of H4(1-20)—3 binding indicates that the interaction is quite
specific. Electrostatic interaction is likely a strong factor, but other modes of interactions such as
van der Waals and hydrogen-bonding may also play significant roles. Based on the results of
CD, fluorescence, and absorption spectral changes, it is quite possible that the secondary
structure of the peptide substrate is altered upon inhibitor binding.
3.2.5. 3 inhibits the activity of histone acetyltransferase (HAT) p300.
The finding that 3 and its analogues inhibit PRMT1 activity by targeting its substrates
implicates that 3 may also inhibit other enzymes that utilize H4 or GAR peptides as substrate. To
test this possibility, we measured the acetylation of H4(1-20) by p300, a well known HAT that is
able to acetylate the N-terminal tail of H4 at multiple sites.(85) The measurement was carried out
with 0.02 μM of p300, 10 μM of [14C]-acetyl CoA, and 10 μM of H4(1-20), at varied
concentrations of 3 or 1. Indeed, both compounds exhibited strong inhibition of p300-mediated
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H4 acetylation (Figure 3.9). The IC50 of 3 and 1 for p300 inhibition were determined to be 21.3 ±
2.0 μM and 118.5 ± 6.5 μM, respectively. Notably, these IC50 values are very similar as those
obtained for PRMT1 inhibition. These data again support our conclusion that the NS-series of
compounds bind to H4 directly, and the binding subsequently prevents H4 from being
recognized by the H4-modifying enzymes, such as PRMT1 and p300. Thus, the inhibition caused
by NS-series compounds depends on the binding between the inhibitor and the substrate,
irrespective of the enzyme targets. On the other hand, although stilbamidine is a competitive
inhibitor in PRMT1-catalyzed methylation, it does not inhibit significantly H4 acetylation
catalyzed by p300 (Figure 3.9d); For example, at 1 mM of stilbamidine concentration, p300 still
retained 84% of its HAT activity. Therefore, quite likely, stilbamidine targets the active site of
PRMT1 to compete with the H4 substrate, which is in agreement with a previous study.(47)
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3.2.6. Suramin inhibits arginine methylation.
The NS-series of compounds have great structural similarity to suramin, a symmetrical
polyanionic aromatic urea containing two naphthalene and six sulfonate groups (Figure 3.1). We
tested whether suramin can inhibit PRMT1-mediated methylation. Indeed, suramin strongly
inhibited arginine methylation on both H4(1-20) and GAR substrate R4, with IC50 of 5.3 μM and
1011 μM, respectively (Table 3.1). As a matter of fact, the inhibition potency of suramin is even
stronger than that of 3, the most potent inhibitor identified from our screening search.
Furthermore, suramin also inhibited the HAT activity of p300 with an IC50 of 13.7 μM (Figure
3.9c). Given their structural analogy and the similar properties in the inhibition of methylation
and acetylation, suramin likely shares the same mechanism of inhibition with NS compounds;
namely suramin also targets H4 and GAR proteins and blocks PTMs on the substrates. These
data clearly revealed a previously unknown function of sumarin.
3.3. Conclusion
In conclusion, we have discovered a type of organic compounds containing naphthalene
and sulfonyl pharmacophore components that inhibit PRMT activity in the micromolar range,
whose inhibition mechanism is fundamentally distinct from the other PRMT inhibitors reported
so far. The biochemical and biophysical data of representative compounds (e.g., 3, 6, 1) show
that these inhibitors are competitive versus PRMT1 substrates (e.g., H4 and GAR peptides) and
noncompetitive versus the methyl donor. Detailed studies illustrate that they directly target the
peptide substrates instead of PRMT1, and the binding subsequently blocks the recognition of the
substrates by the enzyme, which is largely responsible for the observed PRMT1 inhibition effect.
We also show that the anti-parasitic drug suramin is also an effective arginine methylation
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inhibitor. These NS inhibitors will be useful chemical tools for mechanistic study of arginine
methylation and other epigenetic modifications. Further, illumination of the inhibitory
mechanism provides a new insight for understanding the pharmacological effect of these
structurally unique molecules in biological systems.

Figure 3.10. Inhibition mechanism of NS compounds.
3.4. Experimental
3.4.1. Materials
Fmoc-protected amino acids and solid phase resins were purchased from NovaBiochem.
All the screening compounds were obtained from ChemBridge Corporation. Stilbamidine and
allantodapsone were obtained from National Cancer Institute. Suramin was purchased from
Acros Organics. For all the effective inhibitors discovered and tested, including compounds 1,
3—11, suramin, and stilbamidine, their purities were confirmed by analytical C18 reversephased HPLC with H2O/acetonitrile gradient elution to be ≥95%. Radioactive AdoMet and
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acetyl-CoA were ordered from GE Healthcare and Perkin Elmer. Other chemical reagents were
purchased from Fisher, VWR, and Sigma, etc.
3.4.2. Peptide substrates
Peptides were synthesized using the standard solid phase peptide synthesis (SPPS)
protocols, purified with C-18 reversed phase HPLC, and confirmed with MALDI-MS as
previously described.(86) The structural sequence of the NH2-terminal 20 aa peptide of histone
H4, i.e., H4(1-20), is Ac-SGRGKGGKGLGKGGAKRHRK. The structural sequence of the NH2terminal 11 aa peptide of histone H4, i.e., H4(1-11), is Ac-SGRGKGGKGLG. The structural
sequence of the GAR peptide, R4, is Ac-GGRGGFGGRGGKGGRGGFGGRGGFG. The
underlined Rs designate for the methylation sites. The NH2-terminal tail 31 aa peptide of human
H3, H3(1-31), was synthesized and used as a substrate in CARM1 and PRMT6 analyses. The
structural sequence of H4(1-20)FL is Ac-SGRGKGGKGDpr(FL)GKGGAKRHRK. Dpr stands
for

2,3-diaminopropionic

acid.

The

structural

sequence

of

R4FL

is

Ac-

GGRGGFGGRGGK(FL)GGRGGFGGRGGFG. In both cases, the fluorescein (FL) is attached
through the side chain amino group.
3.4.3. Protein expression and purification
His6x-tagged PRMT1 was expressed from pET28b vector. GST-PRMT1 is expressed
from pGEX-4T1 vector. His6x-tagged PRMT3 was expressed from the pReceiver vector. GSTmCARM1 was expressed from the pGEX-4T1 vector. His6x-tagged PRMT6 was expressed from
the pET28a vector. All the proteins were expressed in E. coli BL21(DE3). All the His6x-tagged
proteins were purified on Ni-NTA beads, and the GST-tagged proteins were purified on
glutathione agarose beads. Protein concentrations were determined using Bradford assay.
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3.4.4. Virtual screening
The virtual screening was conducted on a 40-node Linux cluster at Georgia State
University using the same protocol as described before.(87, 88) The 2D structures of
ChemBridge database (about 0.4 million compounds) were first converted into 3D structures by
using the CONCORD program.(81) Hydrogen atoms were then added to the 3D ligand structures
and all atoms were assigned with AM1-BCC partial charges(89-91) by the QuACPAC 1.1
software.(92) These structures were firstly examined based on drug-like property by the FILTER
2.0.1 software.(93) Before docking-based virtual screening, the PRMT1 structure (PDB entry:
1OR8) was added with hydrogen atoms and assigned with Kollman-all charges by the SYBYL
7.1 program.(94) Residues including Arg 3, Arg 9, Arg 15, Ile 44, His 45, Met 48, Leu 49, Arg
54, Thr 55, Asp 76, Val 77, Gly 78, Ser 79, Gly 80, Thr 81, Gly 82, Ile 83, Leu 84, Ile 99, Glu
100, Cys 101, Ser 102, Ile 104, Gly 126, Lys 127, Val 128, Glu 129, Ser 143, Glu 144, Met 155
and Thr 158, were defined as the active site to construct a grid for the structure-based virtual
screening. The position and conformation of each compound were optimized firstly by the
anchor fragment orientation and then by the torsion minimization method implemented in the
DOCK 6 program.(82) Fifty conformations and a maximum of 100 anchor orientations for each
compound were generated, and all of the docked conformations were energy minimized by 100
iterations following procedures as described in literature.(82) The docked molecules were ranked
based on the sum of the van der Waals and electrostatic energies implemented in the DOCK 6
program to obtain the top 1000 compounds. After collecting the top hits, the consensus scoring
evaluation(95), including ChemScore,(96, 97) PLP,(98) ScreenScore,(99) ChemGauss and
ShapeGauss(100) implemented in the FRED 2.2.3 program, was processed,(93) as well as
hydrogen bond and hydrophobic profiles by the IDEA 8.8 software.(101) As the final step, a
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manual binding orientation and conformational examination was performed to harvest the final
fifty hits for biochemical evaluation.
3.4.5. Radioactive methylation assay
The inhibitory activities of small molecule compounds were tested using carbon-14
labeled radioactive methylation assays. The assays were carried out in 0.6-mL plastic tubes at
30°C in a reaction volume of 30 μL. The reaction buffer contained 50 mM HEPES (pH = 8.0),
0.5 mM DTT, 1 mM EDTA, and 50 mM NaCl. In a typical procedure, 2 μM of peptide substrate,
5 μM of [14C]-AdoMet and varied concentrations of an inhibitor were preincubated in the
reaction buffer for 5 min prior to the initiation by the addition of PRMT1 (0.1 μM final). After
incubating for an appropriate period of time, the reaction was quenched by spreading the reaction
mixture onto P81 filter paper discs (Whatman). The paper disc was washed with 1 liter of 50 mM
NaHCO3 and dried in air for 2 hours. The amount of methylated products was quantified by
liquid scintillation. IC50 value is the concentration of inhibitor at which half of the maximal
activity is reached. The Ki for stilbamidine was calculated from IC50 by using the equation:
. Km was obtained by measuring the initial velocity of reaction at different

concentrations of a particular substrate and fitting the kinetic data with Michaelis-Menton
equation. The inhibition patterns of 3 and 6 were determined by measuring initial velocities of
PRMT1 at a range of varied concentrations of one substrate, a fixed concentration of the other
substrate, and selected concentrations of the inhibitors. The data were displayed in double
reciprocal formats and fitted to competitive or noncompetitive kinetic equations.(102)
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3.4.6. Inhibition of p300 catalysis
Recombinant p300 HAT domain (1287-1666) was a gift from Dr. Philip Cole at Johns
Hopkins University and its expression was described in an earlier report.(103) Enzymatic
activity of p300 and its inhibition by 3 and other compounds were measured by radioactive
acetylation assays. A reaction mixture of 10 μM of H4(1-20), 10 μM of [14C]-acetyl CoA, 20 nM
of p300, and increasing concentrations of the inhibitors were incubated in the reaction buffer (50
mM HEPES (pH 8.0), 50 mM NaCl, 0.5 mM DTT, 1 mM EDTA) at 30 ºC for 10 min, and the
reaction was quenched by loading the mixture onto p81 filter paper. The radioactive products
were quantified by liquid scintillation and the fractional activity of p300 was plotted in respect to
the concentration of individual inhibitors.
3.4.7. Fluorescent binding assay.
Fluorescence intensity and anisotropy of fluorescein-labeled peptides were measured on a
Fluoromax-4 spectrofluorometer (Horiba Jobin Yvon). The buffer was the same as that for the
radioactive assay. The excitation wavelength and emission wavelength were selected at 498 nm
and 524 nm, respectively. The competitive binding of small molecule compounds to PRMT1substrate solution was measured using the fluorescence anisotropy mode in similar manners as
described previously.(83) Typically, 0.2 μM of H4(1-20)FL and 2 μM of PRMT1 were mixed,
and increasing concentrations of an inhibitor were added until the fluorescence anisotropy
signals leveled off. The anisotropy values at 524 nm from several scans were plotted as a
function of inhibitor concentration. Data were fitted with competitive binding model using
DynaFit program to calculate the Ki value.(84, 104) Also, fluorescence intensity changes of
H4(1-20)FL at different concentrations of 3 were measured in order to detect their interaction.
0.2 μM of H4(1-20)FL at 30ºC was titrated with increasing concentrations of 3 (0 ~ 28.2 μM).
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NHS-fluorescein was used as a control. The fluorescence intensities of both H4(1-20)FL and
NHS-fluorescein were corrected to remove the inner filter effect that was caused by 3 absorption,
and the data were plotted as a function of the concentration of 3. The Job’s Method was applied
to determine the binding stoichiometry of 3 with H4(1-20)FL. A series of solutions with a fixed
total amount (0.225 nmol) but varied ratios (0~9) of 3 and H4(1-20)FL in the same reaction
buffer were prepared. The fluorescence intensity of each sample at 524 nm was measured, which
is related to the amount of binding complex. The fluorescence intensity was divided by the molar
fraction of H4(1-20)FL, and then plotted as a function of the molar fraction of 3.
3.4.8. UV-Vis spectroscopy of 3 upon titration with H4(1-20) or PRMT1.
The UV-Vis spectra of compound 3 (40 μM in the same reaction buffer) were acquired
on a Shimadzu UV-1700 spectrophotometer, in the presence of different concentrations of H4-20
or PRMT1.
3.4.9. CD measurement.
CD spectral changes of H4(1-20) upon the addition of different concentrations of 3 were
measured on a Jasco J-810 spectropolarimeter. 100 μM H4(1-20) was titrated with 0 μM, 100
μM, and 200 μM of 3 in 10 mM Tris buffer (pH 7.4) in a 400 μl CD cuvette. CD spectrum of
each equilibrated sample was scanned (100 nm/min) with an accumulation of 3 times.
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CHAPTER 4
A TRANSIENT KINETIC ANALYSIS OF PRMT1 CATALYSIS
(This work is mainly based on the published paper, Biochemistry. 50 (2011) 7033-44. In this
project, the author is obliged to Dr. Nan Xie and Miyeong Jin for their contributions to prepare
the peptide compounds, and Dr. Mary R. Stahley and Dr. James T. Stivers for their assistance in
stopped-flow fluorometer analysis.)
4.1. Introduction
Arginine methylation of the core histones is catalyzed by protein arginine
methyltransferases (PRMTs), which transfer the methyl group from S-adenosyl-L-methionine
(SAM) to the guanidino group of specific arginine residues. Thus far, about nine PRMT
members have been identified at the proteomic level in mammalian cells and these have been
grouped into two major types (type I and type II) according to their product specificity (18-20).
Type I enzymes (PRMT1, 2, 3, 4, 6, and 8) catalyze the transfer of the methyl group from SAM
to one guanidino nitrogen atom of arginine residue to produce ω-NG monomethylarginines
(MMA, L-NMMA) and ω-NG, NG-asymmetric dimethylarginines (ADMA) [for a review, see a
ref. (21)]. Type II enzymes (e.g., PRMT5) catalyze the formation of MMA and ω-NG, N’Gsymmetric dimethylarginines (SDMA) (24-27). As a result of the methyl transfer, SAM is
converted to the product S-adenosyl-L-homocysteine (SAH). PRMTs can exhibit quite high
substrate specificity which is correlated with their different specific functions. For instance,
CARM1 (PRMT4) methylates H3R2, H3R17 and H3R26 (65, 105), while PRMT1 and PRMT5
specifically methylate H4R3 and H3R8 (40, 76). The methylation at distinct sites can affect the
status of gene expression differently. For instance, asymmetric dimethylation at H3R17 and
H4R3 stimulates gene activation, whereas symmetric dimethylation at H4R3 is associated with
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gene repression (40, 106, 107). In general, PRMT-catalyzed arginine methylation is essential for
many biological processes including gene transcriptional regulation (40, 56, 76, 105, 106, 108,
109), signal transduction (110-113), RNA transport (24, 114), RNA splicing (57, 115), DNA
repair, and embryonic development and cellular differentiation (58, 116, 117).
Scheme 4.1. PRMT1-catalyzed arginine methylation.
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Several studies of the kinetic mechanism of arginine methylation have been recently
reported. One steady-state kinetic analysis suggested that PRMT1 utilizes a rapid equilibrium
random mechanism (RER) for methyl transfer with the formation of dead-end EAP and EBQ
complexes (33). In another study, PRMT6 was shown to follow an ordered sequential
mechanism in which SAM binds to the enzyme first and the methylated product is the first to
dissociate (34). The slight difference in these two studies may suggest that kinetics of arginine
methylation can vary slightly among the individual isoforms. Nevertheless, both studies support
a sequential kinetic mechanism in which a ternary complex is formed prior to the methyl transfer
step.
Many important questions about the PRMT-catalyzed arginine methylation reaction
remain to be answered. For instance, it is not known whether the chemical step or a protein
conformational change in the ES complex is rate-limiting for catalysis. Such a molecular level
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understanding of how substrate recognition is coupled to catalysis will be of great significance to
evaluate the function of PRMT activity in different physiological contexts. To address these
mechanistic questions, transient kinetic analyses of arginine methylation are highly desirable.
Unfortunately, such studies are greatly limited by lack of assay tools appropriate for fast
measurement of substrate binding and methylation on rapid time-scales. In particular, routine
radioisotope-labeled methyl transfer assays do not provide information about conformational
events along the reaction coordinate. Recently, we reported fluorescently labeled peptide
substrates that could be useful in studies of substrate binding and methylation (118). Here we
report that such substrates serve as excellent tools to dissect the transient kinetic events during
PRMT1 catalysis. By using fluorophore-labeled H4 substrates in combination with stopped flow
measurements, we have determined the microscopic rate constants for the key binding and
methylation steps during PRMT1 catalysis. This study provides kinetic evidence that substrate
recognition induces a conformational transition of the active site of PRMT1, and strongly
indicates that the methyl transfer step is overall rate-limiting for arginine methylation. In
addition, we find that binding of the cofactor SAM/SAH modulates the interaction between
PRMT1 and the peptide substrate.
4.2. Results and Discussion
4.2.1. Oligomerization of PRMT1 stimulates its activity.
To understand the process of methylation, we first checked the oligomeric state of
PRMT1, as this enzyme has been reported to function as a homo-dimer or oligomers (30).
Different concentrations of PRMT1 were incubated with glutaraldehyde (0.025%, v/v) for 5 min.
0.1% Triton X-100 was added to eliminate the nonspecific interactions. The mixtures were
resolved using 8% SDS-PAGE and probed with anti-PRMT1 antibody. It is clear that as the
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protein concentration increases, the degree of oligomerization also increases until it reaches a
plateau (Figure 4.1a and b). We further tested if there is a correlation between the activity of
PRMT1 and its concentration. As Figures 4.1c and 4.1d reveal, the slope of a plot of the apparent
Vmax divided by PRMT1 concentration (i.e. the apparent kcat) is not constant as the PRMT1
concentration changes. In other words, the turnover rate per PRMT1 monomer becomes higher
as its concentration increases, and then plateaus when it rises above ~0.5 μM. Together, these
data suggest that PRMT1 oligomerization is dependent on concentration in the range of 0 to 0.5
μM, and that the final PRMT1 oligomeric complex is the most active form.
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Figure 4.1. Concentration dependence of PRMT1 oligomerization and catalytic
activity. (a) Western blot analysis of PRMT1 oligomerization. Different concentrations of
PRMT1 (0.012 μM ⎯ 3.13 μM) were prepared in presence of 0.1% Triton X-100 and incubated
with 0.025% (v/v) glutaraldehyde for 5 min. The crosslinked proteins were resolved on 8% SDSPAGE followed by western blot detection (primary antibody: anti-PRMT1 rabbit polyclonal IgG;
secondary antibody: goat anti-rabbit IgG-HRP). Lane 1 to 9: marker, 0.012 μM, 0.024 μM, 0.05
μM, 0.10 μM, 0.20 μM, 0.39 μM, 0.78 μM, and 1.56 μM of PRMT1. (b) Concentrationdependent oligomerization of PRMT1. The western blot densitometry was analyzed by Quantity
One software, and the fractions of PRMT1 monomer, dimer and oligomer were plotted as a
function of PRMT1 concentration. (c) Maximum velocity as a function of PRMT1 concentration.
0 ~ 3.13 μM of PRMT1 was added to the reaction buffer containing 18.75 μM of [14C]-SAM and
18.75 μM of H4-20. The total protein concentration for each reaction was controlled at 3.13 μM
by including BSA as a carrier protein, eliminating the effect of nonspecific interaction. Each
reaction was quenched at less than 20% yield. (d) Apparent kcat as a function of PRMT1
concentration. The data were deduced from (c) by dividing the maximum velocity with the
corresponding enzyme concentration.

4.2.2. H4 peptide synthesis and steady-state kinetic characterization.
To create fluorescent probes for study of the PRMT-substrate interaction and
methylation, we synthesized several peptides containing N-terminal 20 amino acids of histone
H4, with 0, 1 or 2 methyl groups on Arg-3 and a fluorescein group on Dpr-10 (2,3diaminopropionic acid residue, substituting for Leu-10) (Table 4.1). H4FL and H4FLme1 are
substrates of PRMT1, and H4FLme2 is a product of PRMT1 catalysis. In this design, the
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fluorescein group is placed at an optimized position relative to the methylation site, such that the
label does not affect substrate methylation but might still be sensitive to the local change in
microenvironment induced by ligand binding. These fluorescent peptides were synthesized with
the Fmoc-based solid phase peptide chemistry strategy, purified by HPLC, and analyzed by
MALDI-MS.
Table 4.1. Sequences of H4 peptides.
Dpr: 2,3-diaminopropionic acid residue; FL: fluorescein group; me: methyl group.
Peptide name

Sequence

H4(1-20)

Ac-SGRGKGGKGLGKGGAKRHRK

H4FL

Ac-SGRGKGGKGDpr(FL)GKGGAKRHRK

H4FLme1

Ac-SGRme1GKGGKGDpr(FL)GKGGAKRHRK

H4FLme2

Ac-SGRme2GKGGKGDpr(FL)GKGGAKRHRK

After the peptide synthesis and characterization, we measured the steady-state kinetic
parameters of PRMT1 catalysis with these substrates. [14C]-SAM was used as the methyl donor
for the methyltransferase reactions, enabling us to quantify the methylated products by liquid
scintillation counting. In the steady-state initial rate assays, one substrate concentration was
varied and the other substrate was fixed in large excess (at least five-fold higher than its Km) to
ensure pseudo first-order reaction conditions. Each reaction was quenched at an appropriate time
to ensure that substrate conversion was less than 20%. As shown in Table 4.2, the Km and kcat
values of peptide for H4(1-20) and H4FL vary by less than three-fold, indicating that fluorophore
does not significantly affect substrate methylation by PRMT1. Also, in a competitive
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fluorescence anisotropy assay, H4(1-20) was found to completely reverse the binding of H4FL to
PRMT1 (Figure 4.3), indicating that the fluorescein-labeled peptide has the same binding mode
to the enzyme as the label-free peptide. In addition, these synthesized peptide substrates exhibit
comparable kinetic parameters as histone H4 protein, demonstrating that they are good
representatives of H4 protein. The kcat/Km values for un-methylated H4FL and mono-methylated
H4FLme1 are 0.86 ± 0.09 μM-1 min-1 and 1.6 ± 0.29 μM-1 min-1, respectively, suggesting that
PRMT1 has little preference for arginine-mono-methylated H4 peptide. The binding affinity
between the fluorescein-labeled peptides and PRMT1 was measured by fluorescence anisotropy
titrations (118), taking advantage of the fact that the large enzyme-peptide complex has a larger
correlation time and higher anisotropy than the peptide ligand (Figure 4.2). The Kd values for the
binding of H4FL, H4FLme1 and H4FLme2 to PRMT1 apoenzyme (0.47 ± 0.06 μM, 0.74 ± 0.13
μM, and 0.44 ± 0.09 μM, respectively) are very similar, suggesting that PRMT1 does not
appreciably distinguish among the three peptide forms, although the Km of H4FLme1 (0.17 ±
0.03 μM) is somewhat lower than the other two peptides. It is possible that binding of cofactor
SAM to PRMT1 alters its interaction with the peptide substrate.
Table 4.2. Steady-state kinetic characterization of PRMT1 binding and catalysis.
The radioactive methylation assays were carried out at 30°C and pH 8.0. PRMT1 Concentration
was typically 0.01 μM in the catalytic experiments. Kd values were detected in fluorescence
anisotropy titration using constant fluorescent peptide (0.2 μM) and increasing concentration of
PRMT1.
Substrates

Km, μM

kcat, min-1

kcat/Km, μM-1 min-1

Kd, μM
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H4 protein

1.69 ± 0.39

0.50 ± 0.03

0.30 ± 0.07

-

H4(1-20)

0.64 ± 0.04

0.81 ± 0.01

1.27 ± 0.08

-

H4FL

0.50 ± 0.05

0.43 ± 0.01

0.86 ± 0.09

0.47 ± 0.06

H4FLme1

0.17 ± 0.03

0.27 ± 0.01

1.60 ± 0.29

0.74 ± 0.13

H4FLme2

-

-

-

0.44 ± 0.09

SAM (for H4FL

3.10 ± 0.46

0.48 ± 0.02

0.15 ± 0.02

-

1.59 ± 0.37

0.33 ± 0.02

0.21 ± 0.05

-

methylation)

SAM (for H4FLme1
methylation)
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Figure 4.2. Fluorescence anisotropy titration of fluorescent peptides with PRMT1.
0.2 μM of H4FL (a), H4FLme1 (b) or H4FLme2 (c) was titrated with increasing concentration of
PRMT1 at 30ºC in the reaction buffer mentioned above, and the anisotropy change due to large
ES complex formation was recorded, with 498 nm excitation and 524 nm emission. Data were fit
to eq 1 to calculate the Kd values.
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Figure 4.3. Fluorescence anisotropy change of H4FL binding to PRMT1 followed by
H4(1-20) competitive titration. Data were collected on a Fluoro-Max 4 fluorimeter (Horiba
Jobin Yvon) with the excitation and emission at 498 nm and 524 nm respectively. 0.2 μM of
H4FL (1) and 2 μM of PRMT1 (2) were added into the reaction buffer sequentially to show the
anisotropy increase. Then increasing concentration of unlabeled H4(1-20) were titrated into the
H4FL-PRMT1 mixture to show the anisotropy decay due to the competitive binding of H4(1-20)
and H4FL to PRMT1.
4.2.3. Measurement of the binding rate constants of the H4 peptides with PRMT1.
Our fluorescein-labeled H4 peptide showed an appreciable fluorescence decrease when
mixed with excess amounts of PRMT1, which was reversed by adding increasing concentrations
of unlabeled H4(1-20) (Figure 4.4). This indicates a change in the environment for the
fluorescein group upon substrate-enzyme interaction, and provides a signal to measure the
association rate constant of the fluorescent peptide with PRMT1 using stopped flow
fluorescence. In the transient kinetics experiments, the fluorescent peptide was rapidly mixed
with increasing concentrations of PRMT1 (in large excess over the substrate), and the timedependent fluorescence signal change was monitored to obtain the observed rate constants (kobs).
Typical time courses for H4FL, H4FLme1 and H4FLme2 are shown in Figures 4.5a, 4.5b, and
4.5c. Each averaged data curve was fitted well to a single-exponential function, suggesting no
more than a simple single-step process. The kobs data were calculated and plotted against PRMT1
concentration (Figure 4.5d and Figure 4.6). The association rate constant (kon) was obtained from
the slope of the plot of kobs against PRMT1 concentration to be 40 ± 1 μM-1s-1 for H4FL, 23 ± 1
μM-1s-1 for H4FLme1, and 26 ± 1 μM-1s-1 for H4FLme2.
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Figure 4.4. Fluorescence change of H4FLme1 association followed by H4(1-20)
competitive titration. Data were collected on a Fluoro-Max 4 fluorimeter (Horiba Jobin Yvon)
with the excitation and emission at 498 nm and 524 nm respectively. 2 μM of PRMT1 and 100
μM of SAH were added into the reaction buffer containing 0.4 μM of H4FLme1 sequentially to
show the fluorescence decrease. Then increasing concentration of unlabeled H4(1-20) were
titrated into the bi-subtrate-enzyme mixture to show the fluorescence recovery due to
competitive binding of H4(1-20) and H4FLme1 to PRMT1. (1) H4FLme1 (0.4 μM); (2)
H4FLme1 (0.4 μM) + PRMT1 (2 μM); (3) H4FLme1 (0.4 μM) + PRMT1 (2 μM) + SAH (100
μM).
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Figure 4.5. Stopped-flow measurements of peptide association with PRMT1. Panel
(a), (b), and (c) show the fluorescence change of H4FL, H4FLme1, and H4FLme2 (0.4 μM)
upon mixing with PRMT1 (4 μM) at 30 ºC in the reaction buffer, respectively. Excitation
wavelength was selected at 495 nm and emission ≥510 nm was detected. Each sample was
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injected 4 to 6 times. The black dots show the averaged data points, and the curves are fit with eq
2. Panel (d) shows the observed association rate constant of H4FLme1 plotted against the
concentration of PRMT1. The data were fit to linear eq 4.
(a)

(b)
700

Observed association rate constant (s-1)

Observed association rate constant (s-1)

750
700
650
600
550
500
450
400
350
300

650

600

550

500

450

400
0

1

2

3

4

5

6

PRMT1 concentration (μM)

7

8

0

1

2

3

4

5

6

7

8

PRMT1 concentration (μM)

Figure 4.6. Plot of kobs versus protein concentration obtained from stopped-flow
fluorescence measurements. Panel (a) and (b) show the linearity between the observed
association rate constant and PRMT1 concentration for H4FL and H4FLme2, respectively. 0.4
μM fluorescent peptide was mixed with increasing concentration of PRMT1 (2, 4 and 6 μM) at
30 ºC in the reaction buffer. Excitation was 495 nm and emission was ≥510 nm. Each sample
was injected 4~6 times.

4.2.4. Measurement of dissociation rate constants of peptides from PRMT1.
We next measured dissociation rate constants (koff) of H4FL, H4FLme1, H4FLme2 from
PRMT1. A trapping experiment was designed as previously described (119). In this
measurement, one solution containing 0.4 μM fluorescent ligand and 2 μM PRMT1 was rapidly
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mixed with the other solution containing a large excess of unlabeled H4 peptide, i.e., 50 μM of
H4(1-20). Following mixing, the fluorescent ligand dissociated from the PRMT1 complex, and
the free PRMT1 was trapped with excess H4(1-20). The single-exponential time course reflects
this dissociation process, with the expected recovery of fluorescence of the labeled peptide as it
is released to bulk solution (Figure 4.7). The dissociation rate constants obtained from these
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Figure 4.7. Stopped-flow measurements of peptide dissociation from PRMT1. 0.4
μM fluorescent peptide was premixed with 2 μM PRMT1 in the reaction buffer. The solution
was then rapidly mixed with 50 μM H4(1-20) on stopped-flow instrument at 30 ºC. Each sample
was injected 4 to 6 times. The black dots show the averaged data points, and the curves are fit
with eq 2. (a), (b), and (c) show the dissociation time courses of H4FL, H4FLme1, and
H4FLme2 from PRMT1, respectively.
4.2.5. Effect of SAH on enzyme binding and dissociation of H4FLme1.
We also examined how the cofactor analog SAH affects the association and dissociation
of the fluorescent substrate H4FLme1 with PRMT1. For the binding experiment, 100 μM of
SAH was preincubated with PRMT1 (2, 4, and 6 μM) prior to rapid mixing with H4FLme1. The
time course for PRMT1-SAH binding with H4FLme1 was monitored with stopped-flow
fluorescence (Figure 4.8a). It is noted that the magnitude of the fluorescence change of
H4FLme1 upon association with PRMT1-SAH is 2-fold larger than its binding with apo PRMT1
under the same condition (Figure 4.5b), and the association rate constant is two-fold higher
(Table 4.3), indicating that SAH modulates the microenvironment of the fluorophore in the ES
complex. More importantly, the time course data can only be fitted to a double exponential
function, rather than a single exponential function as observed above, suggesting that the binding
is not a single-step process and that minimally two steps are involved (Scheme 4.2b). The double
exponential fitting produces two sets of kobs, one for a fast phase and the other for a slow phase
(phase 1 and phase 2 in Figure 5a, 5b). The rate constant values can be further fit to a two-step
binding model (eq 5) (120). The first-step binding rate constant k1 was determined from the slope
of the fast phase as 48 ± 1 μM-1s-1. The plateau of the slow phase (36 ± 2 s-1) corresponds to the
sum of k2 and k-2, and the difference on the ordinate axis between this plateau and the intercept of

77

the fast phase yields 117 ± 3 s-1 for k-1. Also, we measured the dissociation progression course for
H4FLme1 from PRMT1 in the presence of 100 μM SAH (Figure 5c). Similar to the dissociation
experiment for the H4FLme1⎯PRMT1 complex, excess H4(1-20) was used as the trapping
ligand. Again, the dissociation time course could not be fitted to a single exponential function,
confirming that the binding of H4FLme1 with PRMT1-SAH is not a single-step process. The
two rate constants obtained from the double exponential fit (109 ± 1 s-1 and 19 ± 0.2 s-1)
correspond to the two reverse rate constants in the two-step binding model (k-1 and k-2 in Scheme
4.2b). Of note, the k-1 value from the trapping experiment is very close to that obtained from the
binding experiment, supporting the validity of the two-step model. Combining the kinetic data
for binding and dissociation, all the four rate constants of Scheme 4.2b were calculated. The koff
for H4FLme1 dissociation from PRMT1-SAH complex is about three-fold lower than that of
apo-PRMT1 (Table 4.3). In addition, the presence of 100 μM SAH or SAM was found to have a
similar effect on the dissociation of H4FLme2 from the PRMT1-cofactor complex as described
above (Figure 4.8d and Figure 4.9), lowering its koff to 204 ± 3 s-1 or 163 ± 3 s-1, respectively.
The kinetic difference between H4 peptide binding to holo-PRMT1 and to apo-PRMT1 suggests
that the presence of the cofactor modulates the PRMT1-substrate interaction.
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Figure 4.8. Effect of SAH on the binding and dissociation of H4 substrate. Panel (a)
shows the fluorescence change of H4FLme1 (0.4 μM) upon mixing with a solution containing 4
μM PRMT1 and 100 μM SAH at 30 ºC in the reaction buffer. The data are fit with a doubleexponential function (eq 3). The observed rate constants for phase 1 and phase 2 are plotted
against the concentration of PRMT1 (or PRMT1-SAH complex), and the data are fit to eq 5 to
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get the four rate constants for the two phases, as shown in panel (b). Panel (c) and (d) show the
dissociation time course of H4FLme1 and H4FLme2 from PRMT1-SAH complex, respectively.
0.4 μM fluorescent peptide was premixed with 2 μM PRMT1 and 100 μM SAH in the reaction
buffer. The solution was then rapidly mixed with 50 μM H4(1-20) on stopped-flow instrument.
The data are fit to eq 3.
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Figure 4.9. Stopped-flow measurement of H4FLme2 dissociation from PRMT1SAM complex. 0.4 μM fluorescent peptide was premixed with 2 μM PRMT1 in presence of 100
μM SAM in the reaction buffer. The solution was then rapidly mixed with 50 μM H4(1-20) on
stopped-flow instrument at 30ºC. The sample was injected 4~6 times. The black dots show the
averaged data points, and the curve is fit with a double exponential equation (eq 3).
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Scheme 4.2. Two different kinetic models of substrate association with PRMT1
apoenzyme and holoenzyme. (a) Single-step binding model between H4FLme1 and PRMT1.
(b) Two-step binding model between H4FLme1 and PRMT1-SAH complex. E: open-state
PRMT1. E’: closed-state PRMT1.
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4.2.6. Progression of arginine methylation probed by stopped-flow fluorescence.
Having determined the binding and dissociation rate constants of H4 substrates and
products, we then investigated possible fluorescence signal changes that reflect PRMT1mediated methylation. Toward this end, we measured the fluorescence changes of H4FL and
H4FLme1 over the entire methylation reaction course (Figure 4.10a and 4.10b). In the stoppedflow experiments, a solution containing 2 μM PRMT1 and 100 μM SAM was mixed with a
solution containing 0.4 μM fluorophore-labeled substrate to initiate the methylation. Such singleturnover conditions increase the chance of identifying active enzyme intermediates. Interestingly,
a biphasic time course was observed. The fluorescence signal for the first phase decreased (phase
I), and then gradually increased until a plateau was reached (phase II). A double exponential
function was applied to determine the rate constants for the two phases (0.14 ± 0.01 s-1 and 0.022
± 0.001 s-1 for the methylation of H4FL, and 7.2 ± 0.2 s-1 and 0.034 ± 0.001 s-1 for the
methylation of H4FLme1). The second phase, i.e. the slower phase, likely reflects the methyl
transfer step because the rate constants are in the same range as the kcat values measured from the
steady-state experiments (0.43 ± 0.01 min-1, 0.27 ± 0.01 min-1, Table 4.2). Also, product release
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cannot contribute to the slow phase given that the dissociation rate constants of H4FLme1 and
H4FLme2 (Table 4.3) are several thousand-fold larger than the rate constants for the slow phase.
On the other hand, the fast phase observed in the time course is of great interest. It does not
relate to the substrate binding, because the observed first-order rate constants for binding of the
substrate (e.g., 248 ± 3 s-1 for H4FLme1 at 2 μM of PRMT1 in presence of the cofactor) are
significantly greater than the rate constants for phase I in the methylation experiments (i.e., 0.14
± 0.01 s-1, 7.2 ± 0.2 s-1). Indeed, if a closer look is taken at the very early part of the first phase
(Figure 4.10a and 4.10b, inlets), an even faster phase can be discerned, which likely corresponds
to the substrate binding step. Therefore, the first phase in the methylation course reveals a new
step existing after the ternary complex formation, and prior to the methyl transfer step. Most
likely, the newly discovered step corresponds to an enzyme isomerization step towards a
catalytically active form in preparation for methyl transfer.
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Figure 4.10. Time course of PRMT1 catalysis probed by stopped-flow fluorescence.
(a) H4FL was used to probe the progression of two methyl transfer; and (b) H4FLme1 was used
to detect the progression of the second methyl transfer. In both measurements, 0.4 μM
fluorescent peptide was mixed with a solution containing 2 μM PRMT1 and 100 μM SAM at
30ºC in the reaction buffer. Each reaction was performed 4 to 6 times, and the black dots show
the averaged data points. The data are fit with eq 3. Inlet graphs magnify the data points at the
very early stage of the reaction.
Table 4.3. Summary of rate constant data obtained from stopped-flow fluorescence
measurements. * indicates the rate constant for the fast phase (phase 1) calculated from doubleexponential fitting.

Rate
constants

Association

Association

Dissociation

with

with PRMT1-

from

PRMT1

SAH

PRMT1

SAH

SAM

methylation

-1

-1

-1

-1

-1 -1

-1 -1

Dissociation

Dissociation

from PRMT1- from PRMT1-

First phase in
the course of

(μM s )

(μM s )*

(s )

(s )

(s )

(s )

H4FL

40 ± 1

-

333 ± 9

-

-

0.14 ± 0.01

H4FLme1

23 ± 1

48± 1

292 ± 3

109 ± 1*

-

7.2 ± 0.2

H4FLme2

26 ± 1

-

319 ± 6

204 ± 3 s*

163 ± 3*

-

Peptides

Second
phase in the
course of
methylation
(s-1)
0.022 ±
0.001
0.034 ±
0.001
-
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Scheme 4.3. Proposed minimal kinetic model of PRMT1 catalysis. (a) first
methylation and (b) second methylation of H4. The chemical step is rate-limiting. E: open-state
PRMT1. E’: closed-state PRMT1.
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(a) E SAM
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E' SAM H4me1

109 ± 1 s-1

E' SAH H4me2

34 ± 0.5 s-1
E SAH H4me2

E SAH + H4me1

204 ± 3 s-1
E SAH + H4me2

4.3. Conclusion
Our stopped-flow fluorescence data provide a detailed view of arginine methylation
catalyzed by PRMT1. Under this scheme, the methyl transfer step is the major rate-limiting step
which proceeds much more slowly than substrate association/dissociation. Binding of cofactor
SAM/SAH appreciably affects the interaction between H4 peptide and the enzyme, probably due
to a conformational change upon enzyme-cofactor complex formation. Importantly, the transient
kinetics data reveal a conformational transition step following the substrate binding and prior to
the chemical step. This protein isomerization likely reorganizes the active site of PRMT1 from
an open state to a closed state, activating the side-chain terminal nitrogen of H4R3 and/or the
reactive methyl group of SAM to facilitate the methyl transfer. Further structural studies will be
essential to validate this kinetic proposition.
4.4. Experimental
4.4.1. Design and synthesis of modified H4 peptides
The amino-terminal peptide of histone H4 containing the first 20 amino acid residues
with different methylation patterns and a fluorescein group were synthesized using Fmoc [N-(9fluorenyl) methoxycarbonyl]-based solid phase peptide synthesis (SPPS) protocol on a PS3
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peptide synthesizer (Protein Technology. Tucson, AZ) as described previously (86). Each amino
acid was coupled to the solid phase with 4 equivalents of amino acid/HCTU [O-(1H-6Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate]

(Novabiochem,

Darmstadt, Germany). The Fmoc group was deprotected with 20% v/v piperidine/DMF, and the
N-terminal amino acid was acetylated with acetic anhydride. The peptide was cleaved from the
Wang resin by a cleavage solution consisting of 95% trifluoroacetic acid (TFA), 2.5% H2O and
2.5% triisopropylsilane. It was then precipitated in cold ether and pelleted by centrifuge. Crude
peptides were collected and purified using a Varian Prostar instrument equipped with a C18
Reversed-phase High Performance Liquid Chromatography (RP-HPLC) column, where 0.05%
TFA-containing water and 0.05% TFA-containing acetonitrile were two mobile phases used in
gradient purification. The purity and identity of peptides were confirmed by MALDI-MS. For
the peptides linked to a fluorescein group, their concentrations were calibrated according to the
absorption of fluorescein at 492 nm.
4.4.2. Expression and purification of PRMT1
Recombinant His-tagged rat PRMT1 was expressed in E. coli and purified with Nicharged His6x-tag binding resin as reported previously (121). Briefly, the PRMT1-pET28b
plasmid was transformed into BL21(DE3) (Stratagene). Transformed bacteria were incubated in
LB media at 37ºC for growth, and then 16ºC for protein expression which was induced by 0.3
mM IPTG. Cells were harvested by centrifuge and lysed by French Press. The supernatant
containing PRMT1 protein was loaded onto the Ni-charged His6x-tag binding resin (Novagen)
that was equilibrated with column buffer (25 mM Na-HEPES, pH 7.0, 300 mM NaCl, 1 mM
PMSF, and 30 mM imidazole). Beads were washed thoroughly with column buffer, followed by
washing buffer (25 mM Na- HEPES, pH 7.0, 300 mM NaCl, 1 mM PMSF, and 70 mM
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imidazole), and protein was eluted with elution buffer (25 mM Na-HEPES, pH 7.0, 300 mM
NaCl, 1 mM PMSF, 100 mM EDTA, and 200 mM imidazole). Different eluent fractions were
checked by 12% SDS-PAGE, and PRMT1 concentration was determined by Bradford assay.
4.4.3. Chemical crosslinking and Western blotting of PRMT1 oligomers
To study the relationship between PRMT1 oligomerization and concentration, His6xrPRMT1 was diluted in the range of 0.012 μM ~ 3.13 μM with storage buffer (25 mM HEPES
(pH 7.0), 250 mM NaCl, 1 mM EDTA, 10% glycerol, and 1 mM DTT) containing 0.1% Triton
X-100, and incubated at 4 ºC overnight. Then PRMT1 was cross-linked with 0.025% (v/v)
glutaraldehyde at room temperature for 5 min. The reactions were quenched by addition of SDS
loading buffer, and PRMT1 proteins were separated by 8% SDS-PAGE followed by western blot
detection, with anti-PRMT1 rabbit polyclonal IgG (Upstate) as the primary antibody and goat
anti-rabbit IgG-HRP (Millipore) as the secondary antibody. After washing away the unbound
probes, PRMT1 bands were visualized using the SuperSignal West Pico Trial Kit (Thermo
Scientific). The film image was analyzed by Quantity One, and the molar fraction of PRMT1
monomer, dimer and oligomer were plotted against PRMT1 concentration.
4.4.4. Radioactive methyltransferase assay
The methylation assays of different H4 peptides or protein were performed using

14

C-

isotope labeled SAM at 30 °C. The reaction buffer contained 50 mM HEPES (pH 8.0), 50 mM
NaCl, 1mM EDTA and 0.5 mM DTT. H4 substrate and [14C]-SAM were preincubated in the
reaction buffer for 5 min prior to initiation of the methyl transfer reaction by adding PRMT1
(0.01 μM typically). The reaction time was controlled under initial rate conditions such that
typical reaction yields were less than 20%. The reaction was quenched by spotting the reaction
mixture on P81 filter paper disc (Whatman). After the paper discs were washed with 50 mM
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NaHCO3 (pH 9.0) and air dried, liquid scintillation counting was performed to measure the
amount of methylated products. Values for Km and kcat were obtained by measuring the initial
velocity of the reaction at various concentrations of one substrate and fixed saturating
concentration of the other substrate (cofactor). The kinetic data were fitted to the MichaelisMenton equation using non-linear regression methods.
4.4.5. Equilibrium fluorescent titration
The Kd value for PRMT1 and the fluorescent peptide binding was measured by
fluorescence anisotropy methods. Increasing concentrations of PRMT1 were added to a constant
concentration of fluorescent peptide (0.2 μM) at 30ºC in the same buffer mentioned above. The
anisotropy increase due to the formation of large ES complexes was recorded with a Fluoro-Max
4 fluorimeter (Horiba Jobin Yvon). The excitation and emission wavelengths were set at 498 nm
and 524 nm, respectively. Data were fit to eq 1, where P is the fluorescence anisotropy at a given
concentration of PRMT1, A is the amplitude, and kd is the observed dissociation constant
between PRMT1 (E) and H4 peptide (S).

4.4.6. Stopped-flow fluorescence measurements
The transient-state kinetics of association, dissociation and catalytic turnover were
determined by stopped-flow fluorescence assays using several fluorescein-labeled H4 peptides
(H4FL, H4FLme1, H4FLme2) as probes. Binding of the fluorescent peptide to PRMT1 (or
PRMT1-cofactor complex) quenches the peptide fluorescence, while release of the peptide
restores the fluorescence. The transient fluorescence signal change was detected at 30°C on an
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Applied Photophysics stopped-flow equipment using an excitation wavelength of 495 nm and a
long pass emission filter centered at 510 nm. Four to six shots were collected and averaged for
each curve. For the association measurements, increasing concentrations of PRMT1 (2, 4, 6 μM),
with or without 100 μM SAH were mixed with 0.4 μM of fluorescent peptide in the reaction
buffer (50 mM HEPES (pH 8.0), 50 mM NaCl, 1 mM EDTA, 0.5 mM DTT). After averaging the
shot data, the association time courses were fitted to a single exponential function (eq 2) when
the cofactor was absent, or to a double exponential function (eq 3) when the cofactor was
present. In eq 2 and 3, F is the fluorescence intensity at time t, A is the amplitude of the
fluorescence change, and kn are the rate constants. The observed rate constants were plotted
against PRMT1 concentration, and the data were fit to eq 4 (in the absence of SAH) or eq 5 (in
the presence of SAH) to derive the association rate constants kon or k1, respectively. For eq 5, k1
and k-1 are the association and dissociation rate constants, and k2 and k-2 are the forward and
reverse rate constants of phase 2.
F = A*exp(-k*t) + C

(2)

F = A1*exp(-k1*t) + A2*exp(-k2*t) + C

(3)

kobs = kon*[PRMT1] + koff

(4)

kobs = k1*[PRMT1] + k-1 + k2 + k-2

(5)

For the dissociation rate constant measurements, 0.4 μM fluorescent peptide was
prebound to 2 μM PRMT1 (with or without 100 μM SAH/SAM), and the complex was rapidly
mixed with 50 μM unlabeled H4(1-20) peptide to trap the free PRMT1. The averaged shot data
were fitted to eq 2 when the cofactor is absent or to eq 3 when the cofactor is present. Here k (or
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k1) is the dissociation rate constant (koff), and k2 reflects the rate constant for a putative
conformational change before substrate release.
For PRMT1 methylation kinetics in single turnover conditions, H4FL or H4FLme1
peptides were used to probe the reaction rate for transfer of both methyl groups (H4FL) or only
the second methyl group (H4FLme1). In these reactions, 2 μM PRMT1 and 100 μM SAM were
mixed with 0.4 μM H4FL or H4FLme1 in the reaction buffer mentioned above. The methylation
time course exhibited two distinct kinetic phases, and was fitted to a double exponential function
(eq 3), where the observed k2 likely reflects the methyl transfer rate constant. The rate constant
for transfer of the first methyl group (k1’) is calculated from eq 6, where ktot (the total rate
constant for transfer of two methyl groups) is obtained from H4FL methylation time course, and
k2’ (the rate constant for transfer of the second methyl group) is obtained from H4FLme1
methylation time course.
1/ktot = 1/k1’ + 1/k2’

(6)
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CHAPTER 5
HISTONE H4 ACETYLATION DIFFERENTIALLY MODULATES ARGININE
METHYLATION BY AN IN CIS MECHANISM
(This work is mainly based on the published paper, J. Biol. Chem. 286 (2011) 20323-34. In this
project, the author is obliged to Dr. Juxian Wang for her contribution to NMR calibration of the
peptide concentrations and part of PRMT1 activity tests, to Sabrina Asher for her contribution to
the peptide preparation, and to Dr. Ivaylo Ivanov and Carlo Guardiani for the molecular
modeling of peptide structures.)
5.1. Introduction
The nucleosome is the fundamental structural unit of chromatin, in which 146 base pairs
of DNA are wrapped around an octamer of two molecules of each of the four core histones
(H2A, H2B, H3 and H4 proteins). Widespread post-translational modifications (PTMs) of the
histone proteins have been identified, including acetylation, phosphorylation, methylation,
ubiquitination, and ribosylation (5, 122). The types and sites of modifications and the specific
functions of these PTM marks in modulating chromosomal remodeling and DNA function have
been intensively studied in recent years. In particular, significant amounts of data have pointed
out the functional correlation of histone modification with transcriptional regulation (123, 124).
While certain modifications are shown as representative marks of active transcription (e.g.,
H3K4 methylation, H3K36 methylation, H3 and H4 lysine acetylation, and H2B ubiquitylation),
some others are correlated with transcriptional repression (e.g., H3K9 methylation, H3K27
methylation, H4K20 methylation, and H2A ubiquitylation) (44, 125). Of importance, many
histone PTM marks co-occurring in the same histones can be synergistic or antagonistic with one
another, forming complicated combinatorial histone modification patterns which have been
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proposed to function as a set of multivalent “histone codes” that promote or repress various
chromosomal transactions that occur in the cell (5, 126, 127). Histone PTM patterns provide a
biochemical index for individual cell type and disease state, and correlate with particular
biological phenomena of the cell (128-131). Given the abundance of histone modification marks
and the dynamic changes of histone modification patterns in response to cell types and
differentiation contexts, it remains a challenging biological theme to illuminate the molecular
basis of how histone codes and code networks are biochemically created and manifest their
downstream impacts on chromatin function (127).
The N-terminal tail of histone H4 is heavily modified at several sites, including Ser-1
phosphorylation, Arg-3 methylation, Lys-5, -8, -12, -16, -20 acetylation (i.e., K5ac, K8ac, K12ac
and K16ac), and lys-20 methylation (40, 132-138). These modifications have been shown to be
very dynamic, and distinct histone modification patterns have been observed in different cell
types, or at different developmental stages of life, or in different phases of cell cycle (128, 129,
139, 140). For example, Pesavento et al. (140) characterized H4 modification by using Topdown mass spectrometric approaches coupled with two-dimension liquid chromatography and
identified 42 forms of H4 in HeLa cells each of which contains different modification patterns.
Coon and coworkers used mass spectrometry methods to identify 74 histone H4 isoforms in
differentiating human embryonic stem cells (139). There is a strong need to understand how
these combinatorial PTM patterns are established at the histone tail.
Acetylation represents one of the most frequent modifications at the H4 tail. The
acetylation is introduced by several histone acetyltransferases (HATs), including p300/CBP
(134, 141), Tip60 (142, 143), and yeast protein Esa1 (144). For example, both p300/CBP and
Esa1 acetylate H4 at K5, 8, 12, and 16 in vitro, and in the context of a nucleosome, acetylation of
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K5 and K8 by p300 is preferred (134, 141). K16 is a preferred acetylation site by the MOF
subunit of the MSL and NSL complexes (145, 146). Histone acetylation is reported to affect the
assembly of higher order nucleosome structures (147) and is generally proposed to coactivate
gene expression. Since there are four major acetylation sites at the H4 tail, i.e., K5, 8, 12, 16,
HAT catalysis can produce a total of 16 acetylated H4 isoforms. Effort is needed to address
which acetylation site and which acetylation combination play predominant roles in determining
the transcriptional status of gene loci. H4K16 acetylation has been particularly shown to be a
hallmark of open chromatin and transcriptional activation (148). It is noteworthy to point out that
different acetylation patterns may be correlated with different functions. For example, K5 and
K12 acetylations are known to be predeposition marks, highly enriched prior to chromatin
assembly during S-phase (149, 150). Possibly, the acetylation event may affect gene expression
by influencing or even determining other modifications at the histone tail. This is especially true
given that histone acetylation has been demonstrated in several studies to be an early event and
occur upstream of other modifications (140, 151).
Here, we investigated how different H4 acetylations and their combinations affect
methylation of H4 at Arg-3 (i.e., H4R3me) at the biochemical level. Protein arginine methylation
is catalyzed by protein arginine methyltransferases (PRMTs) which are S-adenosyl methionine
(AdoMet, SAM)-dependent enzymes and generally classified into type I and type II families.
PRMT1 is the predominant member of type I PRMTs and PRMT5 is a representative member of
type II PRMTs in mammalian cells (Figure 5.1). Type I PRMTs are able to transfer up to two
methyl groups from the cofactor AdoMet to one single terminal nitrogen of the guanidino group
of specific arginine residues in a protein substrate, resulting in ω-NG-monomethylarginine
(MMA) and ω-NG,NG-asymmetric dimethylarginine (ADMA) products (19, 21, 23, 24). In
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contrast, Type II PRMT enzymes place one methyl group on each of the two terminal guanidino
nitrogens to form MMA and ω-NG, N’G-symmetric dimethylarginine (SDMA) products (24, 26,
27). Due to the lack of structural information, it is still poorly understood how the
regiospecificity in methylated products is achieved. At the H4 tail, both PRMT1 and PRMT5 are
able to methylate H4R3 in vivo. Of significance, the biological impact of H4R3 methylation by
PRMT1 is opposite to that of PRMT5: PRMT1-mediated dimethylation of R3 is correlated with
gene activation (40), but the methylation of H4R3 by PRMT5 is in many cases associated with
gene repression (76). Our biochemical data show that PRMT1 recognizes and methylates H4
substrates that contain different acetyl marks in a very distinct manner from that of PRMT5, thus
providing a molecular insight into the mechanism of how PRMT1 and PRMT5 target the
chromatin template and how acetylation contributes to the establishment of H4 modification
patterns or codes by an cis-acting mechanism. This finding also unveils a clear distinction
between type I PRMT and type II PRMT with respect to the mode of substrate specificity
regulation.
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Figure 5.1. Methylation of H4R3 by PRMT1 and PRMT5.
5.2. Results
5.2.1. Design, synthesis, and characterization of modified H4 peptide library.
The N-terminal tail of H4 is subject to many PTMs including R3 methylation and
acetylation at K5, 8, 12, and 16 sites. To quantitatively evaluate the in-cis effect of acetylation
marks on R3 methylation, we designed a library of H4 peptides containing the first 20 amino
acids that incorporate all the 16 possible acetylation combinations, including 1 uncetylated, 4
monoacetylated, 6 diacetylated, 4 triacetylated, and 1 tetraacetylated forms (Table 5.1). All
peptides are N-terminally capped with acetic anhydride because virtually all H4 proteins are Nterminally acetylated in vivo (129, 139, 140, 152). These peptides are used as substrates of
PRMT1 and PRMT5 to evaluate how different acetylation combinations affect the methylation
of R3 catalyzed by these two enzymes. It is worthwhile to stress that our data and others have
fully determined that the N-terminal peptide sequence represents an authentic substrate of
PRMTs and its catalytic properties are very similar to that of the full-length H4 protein (33). All
the peptides were synthesized using the standard Fmoc SPPS protocols, purified on C-18
reversed phase HPLC column, and confirmed with MALDI-MS as previously described (86).
Table 5.1. Sequences of synthetic H4 peptides. The ac symbol stands for acetyl group.
Abbreviation
A. wt H4
B. H4K5ac
C. H4K8ac
D. H4K12ac
E. H4K16ac
F. H4K5ac8ac
G. H4K5ac12ac

Sequence
ac-SGRGKGGKGLGKGGAKRHRK
ac-SGRGKacGGKGLGKGGAKRHRK
ac-SGRGKGGKacGLGKGGAKRHRK
ac-SGRGKGGKGLGKacGGAKRHRK
ac-SGRGKGGKGLGKGGAKacRHRK
ac-SGRGKacGGKacGLGKGGAKRHRK
ac-SGRGKacGGKGLGKacGGAKRHRK

MW
calculated
2034.2
2076.2
2076.2
2076.2
2076.2
2118.2
2118.2

MW
measured
2034.1
2076.1
2076.2
2076.2
2076.3
2118.1
2118.4
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H. H4K5ac16ac
I. H4K8ac12ac
J. H4K8ac16ac
K. H4K12ac16ac
L. H4K5ac8ac12ac
M. H4K5ac8ac16ac
N. H4K5ac12ac16ac
O. H4K8ac12ac16ac
P. H4K5ac8ac12ac16ac

ac-SGRGKacGGKGLGKGGAKacRHRK
ac-SGRGKGGKacGLGKacGGAKRHRK
ac-SGRGKGGKacGLGKGGAacKRHRK
ac-SGRGKGGKGLGKacGGAKacRHRK
ac-SGRGKacGGKacGLGKacGGAKRHRK
ac-SGRGKacGGKacGLGKGGAKacRHRK
ac-SGRGKacGGKGLGKacGGAKacRHRK
ac-SGRGKGGKacGLGKacGGAKacRHRK
ac-SGRGKacGGKacGLGKacGGAKacRHRK

2118.2
2118.2
2118.2
2118.2
2160.2
2160.2
2160.2
2160.2
2202.2

2118.2
2118.5
2118.1
2118.3
2160.6
2160.7
2160.3
2160.6
2202.4

Since synthetic peptides typically contain varying amounts of TFA counter ions as a
result of HPLC purification, we sought to determine the accurate concentration of each H4
peptide prior to enzymatic analysis. The NMR spectra of H4 peptides show two very
characteristic peaks at 7.4 and 8.7 ppm which come from the imidazole side chain of His-18
(Figure 5.2). We used the integration ratio between these two peaks and the methyl peak of
standard reagent DSS to calibrate the concentration of each H4 peptide. A typical 1D 1H-NMR
spectrum used for calibration of H4 peptide concentration is shown in Figure 5.2. The use of
NMR calibration to obtain the accurate concentration of H4 peptides is technically critical for
accurately quantifying and comparing the effect induced by individual acetylation marks. As a
matter of fact, varying degrees of difference were observed between weight-based concentrations
and NMR-calibrated concentrations (data not shown).
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Figure 5.2. A typical NMR spectrum used for calibration of H4 peptide
concentration. The NMR solution contained 4.5 mM of H4K16ac peptide and 1 mM of DSS in
D2O.
5.2.2. Impact of H4 acetylation on PRMT1-catalyzed R3 methylation.
Arginine 3 of H4 is methylated by PRMT1. However, the potential effect of acetylation
at K5, 8, 12, and 16 on R3 methylation is not clear. The four acetylations at K5, 8, 12, 16
generate multiple combinations. It remains to determine whether individual combination marks
affect R3 methylation differentially or in a similar manner and which acetyl mark predominantly
modulates R3 methylation.
With the purified H4 library peptides, we tested PRMT1-catalyzed methylation of
individual H4 peptides each of which contains a unique acetylation pattern. The methylation
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reaction was composed of 0.1 µM of PRMT1, 20 µM of [14C]-AdoMet and 100 µM of each
substrate, and the reaction was allowed to proceed for 10 min. The reaction mixtures were
resolved on 16% SDS-PAGE and the methylated products were visualized by phosphorimaging
and quantitated using ImageQuant software (Figure 5.3). At first glance of the experimental data,
it is apparent that some acetylation combinations decrease but some others increase the level of
R3 methylation. In particular K5 acetylation is detrimental to R3 methylation, which alone
decreases R3 methylation by 30%. In combination with other lysine acetylations, e.g., with
K8ac, or K8ac and K12ac, the repressive effect of K5ac is even stronger; the degree of
repression reaches 3 and 5 folds, respectively. On the other hand, K16ac leads to a positive
impact on R3 methylation. K16 acetylation alone increases the PRMT activity by 30%. The
majority of H4 peptides that contain the K16ac mark (except M and P) are slightly better
substrates of PRMT1. For instance, if K16ac coexists with K5ac, K8ac or K12ac, the activation
effect is dominant. Compared to K5ac and K16ac, the effect of K8ac and K12ac in regulating R3
methylation seems quite marginal by itself and is influenced by the presence of K5ac or K16ac
mark. For example, a repressive effect is observed when K8ac co-presents with K5ac, but a
positive effect is observed when K8ac co-presents with K16ac. Overall, these data support that
K5ac and K16ac are two counteractive modification marks that affect R3 methylation in opposite
ways: K5ac is the predominant factor that negatively impacts R3 methylation, and K16ac
positively modulates R3 methylation by PRMT1.
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Figure 5.3. Effects of lysine acetylation on Arg-3 methylation by PRMT1. The
reaction buffer contained 50 mM of HEPES (pH 8.0), 10 mM of NaCl, and 1 mM of DTT. The
concentration of PRMT1, [14C]-AdoMet and H4-20 were 0.1 µM, 20 µM and 100 µM,
respectively. The reaction time was 10 min.
To understand the mechanism by which K5ac and K16ac affect R3 methylation by
PRMT1, we measured the steady-state kinetic parameters of unacetylated and several acetylated
H4 peptides. The data shown in Table 5.2 reveal that for the methylation of H4K5ac peptide, the
kcat decreases by half but there is little change in Km. These data suggest that acetylation of K5
does not cause explicit changes in the substrate binding and recognition by PRMT1. Likely, the
positively charged K5 is required for a methyl transfer step in the catalytic pathway of PRMT1
and acetylation of K5 blocks this key step in the methyl transfer reaction as reflected in its effect
on kcat. On the other hand, acetylation of K16 affects Km more than kcat and V/K is increased from
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1.78 to 3.22 min-1μM-1. Thus, K16ac appears to increase the affinity of enzyme-substrate
association, but has little effect on the catalytic step.
Table 5.2. Steady-state kinetic parameters of PRMT1 catalysis. The methylation of
each peptide by PRMT1 was tested with the radioactive filter binding assay. Varied
concentrations of peptide (0 to 20 μM) and 15 µM of [14C]-AdoMet were incubated at 30ºC for 5
min in the reaction buffer (50 mM HEPES, pH 8.0, 10 mM NaCl and 1 mM DTT). The reaction
was initiated with PRMT1. The methylated products were purified on to P81 filter paper and
quantified by liquid scintillation. Calculated methylation rate was plotted as a function of peptide
concentration and the data were fitted with Michaelis-Menton equation.

A
B
C
D
E
H
J
K

Substrates
wt H4-20
H4(1-20)K5ac
H4(1-20)K8ac
H4(1-20)K12ac
H4(1-20)K16ac
H4(1-20)K5acK16ac
H4(1-20)K8acK16ac
H4(1-20)K12acK16ac

Km, μM
0.34 ± 0.05
0.37 ± 0.06
0.58 ± 0.10
0.27 ± 0.05
0.23 ± 0.05
3.29 ± 0.53
1.11 ± 0.17
0.38 ± 0.07

kcat, min-1
0.64 ± 0.13
0.32 ± 0.01
0.50 ± 0.02
0.47 ± 0.01
0.74 ± 0.06
1.02 ± 0.07
1.33 ± 0.06
0.77 ± 0.03

V/K, min-1μM-1
1.78 ± 0.69
0.86 ± 0.14
0.86 ± 0.15
1.74 ± 0.32
3.22 ± 0.75
0.31 ± 0.05
0.84 ± 0.19
2.06 ± 0.38

Our biochemical data reveal that the impact of H4 acetylation on PRMT1-mediated R3
methylation depends on the individual pattern of acetylation combination. The clear observation
is that K5ac is the predominant modification mark that negatively impacts on R3 methylation by
PRMT1 (Figure 5.3). The lower kcat of H4K5ac methylation with regard to that of the wild type
H4 suggests that the acetyl group on K5 produces a steric or hydrophobic hindrance in the active
site, reducing the ability of PRMT1 in methylating H4R3. Acetylation at K8 and K12 seems to
have minimal effects on R3 methylation, but their presence can augment the impact of K5ac or
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K16ac. Interestingly, K16ac enhances R3 methylation, and to some degree antagonizes the effect
of K5 acetylation. This is slightly different from the result of a previous study showing that all
forms of H4 acetylation repress R3 methylation (40). The difference is likely caused by the
methods used in peptide concentration determination. In our experiments, the peptide
concentrations were accurately calibrated by NMR technique, but in the previous study peptide
concentrations were weight-based. Despite this technical difference, the repressive impact of H4
acetylation on type I methylation of R3 was clearly observed in several acetylated H4 forms
containing the K5ac mark. It is important to mention that our biochemical results coincide well
with the in vivo data that methylated R3 was found to be present with K16ac mark in many H4
isoforms (139, 140) and coexistence of K16ac with R3me was observed in higher histone H4
population than any other acetylated H4 isoforms (140).
The observed acetylation effect also suggests valuable clues about PRMT1-H4
interaction. It seems reasonable that K16ac affects Km, but not kcat, given the remoteness of this
residue to R3 along the H4 backbone chain. The prominent impact of K16 acetylation on R3
methylation is in good agreement with a previous study showing that the amino acid residues on
the H4 tail distal from R3 (i.e., aa 16-20) interact with PRMT1 and contribute to substrate
recognition (153). The crystal structure of PRMT1 highlights that an acidic area exists on the
surface of PRMT1 (80) and suggests that positive charges of substrates are needed for binding to
the enzyme. Here, our data demonstrate that electrostatic interaction does not seem to be the sole
factor determining the PRMT1⎯substrate interaction since K16 acetylation favors the
methylation at R3. This is also supported by the fact that, in H2A, a PRMT1 substrate with
similarity to H4, threonine is placed at the equivalent position of H4K16.
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5.2.3. Impact of H4 acetylation on PRMT5-mediated R3 methylation.
In addition to asymmetric dimethylation by PRMT1, H4R3 can be symmetrically
dimethylated by PRMT5 in vivo. Of great interest is that these two types of dimethylation in
many cases are correlated with opposite functions in gene transcriptional regulation: PRMT1
activates gene expression but PRMT5 represses transcription (40, 76). To understand the
molecular basis of such functional oppositeness, we have examined how H4 acetylation affects
symmetric dimethylation of H4R3 by PRMT5. First, we subjected the 16-mer H4 library
peptides to PRMT5 catalysis under the similar condition as the methylation by PRMT1.
Concentrations of PRMT5, [14C]-AdoMet and H4 peptide were maintained at 0.1 µM, 30 µM
and 200 µM respectively, and the reaction proceeded for 1 h. The methylated products were
resolved on SDS-PAGE and analyzed by phosphorimaging. As shown in Figure 5.4, intriguingly,
most acetylated H4 peptides are better methylated by PRMT5 than the unacetylated H4. This is
in stark contrast with the methylation catalyzed by PRMT1, in which the fully acetylated H4 is a
poor substrate. The preference of acetylated H4 by PRMT5 is further validated by the data of kcat
and Km measurement (Table 5.3). In particular, K5ac upregulates the value of kcat, suggesting
that this modification mark provides favorable contact with the active site of PRMT5 to facilitate
methyl transfer. Also, K16ac increases Km, suggesting that this distal modification mark weakens
the binding affinity of H4⎯PRMT5. Thus, the impacts of K5ac and K16ac are opposite to that
of PRMT1 catalysis.
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Figure 5.4. Effects of acetylation on R3 methylation catalyzed by PRMT5. Reaction
buffer contained 50 mM of HEPES (pH 8.0), 10 mM of NaCl, and 1 mM of DTT. Concentration
of PRMT5, [14C]-AdoMet and H4 peptide were 0.1 µM, 30 µM and 200 µM respectively. The
reaction time was 1 h.
Table 5.3. Kinetic parameters of PRMT5 catalysis. The catalytic activity of PRMT5
on each peptide was tested with the radioactive filter binding assay. Varied concentrations of
peptide (0 to 10 μM) and 30 µM of

14

[C]-AdoMet were incubated at 30ºC for 5 min in the

reaction buffer (50 mM HEPES (pH 8.0), 50 mM NaCl, 1 mM EDTA and 0.5 mM DTT) prior to
the addition of PRMT5. The methylated products were loaded onto P81 filter paper and
quantified by liquid scintillation. Calculated methylation rate was plotted as a function of peptide
concentration and the data were fitted with Michaelis-Menton equation.
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A
B
C
D
E

Substrates
wt H4-20
H4(1-20)K5ac
H4(1-20)K8ac
H4(1-20)K12ac
H4(1-20)K16ac

Km, μM
0.63 ± 0.11
0.38 ± 0.08
0.66 ± 0.14
0.52 ± 0.13
1.20 ± 0.16

kcat, min-1
0.043 ± 0.002
0.079 ± 0.003
0.042 ± 0.003
0.049 ± 0.003
0.048 ± 0.002

V/K, min-1μM-1
0.068 ± 0.012
0.21 ± 0.044
0.064 ± 0.014
0.094 ± 0.024
0.040 ± 0.006

5.2.4. Impact of H4 acetylation on PRMT1 and PRMT5 activity using H4 protein and
nucleosome as substrates.
So far, we used a 16-mer H4 peptide library comprising different acetylation patterns to
dissect the detailed effects of H4 acetylation on the activity of PRMT1 and PRMT5. To further
confirm these results, we investigated methylation of H4 at the protein level by these two PRMT
members. In the experiment, acetylation of recombinant H4 protein was first introduced by
incubation with acetyl-CoA and HAT proteins p300 or MOF. Next, the acetylated H4 protein
was subject to PRMT1 and PRMT5 catalysis using [14C]-AdoMet as the methyl donor. The
reaction mixtures were then resolved on SDS-PAGE and the methylated H4 band was visualized
by storage phosphor imaging. As seen in Figure 5.5, it is clear that acetylation on H4 protein
inhibited its methylation catalyzed by PRMT1, but promoted PRMT5-mediated methylation.
These data coincide well with the peptide methylation data showing that hyperacetylation of H4
inhibited PRMT1 activity but potentiates PRMT5 activity. We also attempted to test such effects
by using nucleosomal substrates. The reconstituted nucleosome was assembled from the
recombinant core histone proteins and a 208-bp 5SrDNA by using the EpiMark protocol (Figure
5.6). However, we found that H4 protein in the context of nucleosome or even in the presence of
DNA (2:1 ratio as is in the nucleosome) was not appreciably methylated by PRMT1 or PRMT5
in our reaction conditions (Figure 5.7). This important observation implicates that DNA
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(especially the unassembled free DNA) poses a physical barrier between nucleosomal histone
and PRMTs, preventing the N-terminal tails of the core histones from being methylated by
PRMTs. Quite likely, arginine methylation of the chromatin template by PRMTs would require
additional accessory proteins or factors in vivo. Another possibility is that the 5SrDNA used here
is not well-suited for nucleosome assembly. If we switch to another nuclear DNA fragment the
methylation result could be different. This DNA effect should be further investigated.
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Figure 5.5. Acetylation on H4 protein inhibits its methylation by PRMT1, while
promotes its methylation by PRMT5. (A) p300-acetylation inhibits H4 methylation by
PRMT1. H4 protein was incubated with Acetyl-CoA in the absence or presence of p300 before
submission to PRMT1 methylation with [14C]-AdoMet. Methylated H4 bands were separated by
15% SDS-PAGE and visualized by storage phosphor scan, which is the same method as for B, C,
and D. (B) p300-acetylation promotes H4 methylation by PRMT5. H4 protein was incubated
with Acetyl-CoA in the absence or presence of p300 before submission to PRMT5 methylation.
(C) MOF-acetylation inhibits H4 methylation by PRMT1. H4 protein was incubated with AcetylCoA in the absence or presence of MOF before submission to PRMT1 methylation. (D) MOF-
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acetylation promotes H4 methylation by PRMT5. H4 protein was incubated with Acetyl-CoA in
the absence or presence of MOF before submission to PRMT5 methylation.

Figure 5.6. Gel shift assay of the
assembled nucleosome. The nucleosomes

▬ nucleosome

were assembled using the EpiMark Nuceosome
Assembly kit with purified recombinant core
▬ unbound
DNA

histones and 5SrDNA (208 bp) according to the

Mixture of 5SrDNA
and core histones

protocol.

The

assembled

nucleosomes were checked by the Gel Shift
Assay

with

6%

native

acrylamide
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Figure 5.7. Assembled nucleosome cannot be methylated by PRMT1 or PRMT5 in
vitro. The methylation of the nucleosome was tested with PRMT1 and PRMT5 in vitro and
compared to H4 protein. 0.21 μM nucleosome or 0.42 μM H4 was incubated with 10 μM [14C]-
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SAM and methyltransferase (0.01 μM PRMT1 or 0.1 μM PRMT5) at 30°C for 65 min, then the
reaction was quenched by SDS loading buffer. The PRMT1 methylation of the recombinant core
histones and the mixture of H4 protein and 5SrDNA (2:1 mole ratio) were also tested as controls.
The methylated protein was separated by 17% SDS-PAGE and visualized by storage phosphor
scan.
5.2.5. The structural changes of H4 induced by acetylation.
It is of great interest to understand the structural basis of the distinct effect of lysine
acetylation on R3 methylation, especially K16ac which is remote from the methylation site. Thus
far, there is no information available on whether and how lysine acetylation changes the structure
of the histone tails in the nucleosome. It could be possible that acetylation causes changes in the
secondary structure of the H4 tail which affects its interaction with PRMTs. To examine whether
there are any structural changes in H4 following lysine acetylation, we measured CD spectra of
wild-type unacetylated H4 peptide (A) and the tetraacetylated H4 peptide (P). In particular, the
CD spectra were measured at different concentrations of TFE (0⎯80%) to determine whether
hydrophobicity of the solvent environment affects the secondary structures (Figure 5.8A and
5.8B). The collected CD spectra were analyzed by Dichroweb, an online server for protein CD
spectra deconvolution (154) to calculate secondary structure contents (helix, strand, turn, and
random coil) for each peptide sample. As shown in Figure 5.8C, the contents of random coils
occupied a high percentage in both A and P. This is not surprising given that the N-terminal
sequence of H4 is invisible in the crystal structures of nucleosome (155), suggesting it is largely
in disordered states. However, we clearly noticed that for the H4 peptide with tetraacetyl marks
(i.e. P), the content of helix and strand became appreciably higher than that of the unacetylated
H4, namely, 36% versus 13%. This suggests that lysine acetylation renders the H4 peptide in

106

more structured states. Furthermore, it was observed that as TFE concentration increased, the
amount of ordered secondary structures appeared to go higher (Figure 5.8D), implicating that
hydrophobic environment favors formation of ordered structures in H4 N-terminal region.
Overall, these data demonstrate that lysine acetylation promotes the tendency of H4 tail to form
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Figure 5.8. Secondary structure analysis of unacetylated H4 peptide (A) and
tetraacetylated H4 peptide (P). CD spectra of unacetylated H4 (panel A) and tetraacetylated H4
(panel B) were measured at different concentrations of TFE (0 ~ 80%) in 20 mM Tris-HCl buffer
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(pH 7.4): black, 0% TFE; blue, 5% TFE; orange, 20% TFE; green, 40% TFE; red, 80% TFE. The
CD data were analyzed by Dichroweb to calculate secondary structure compositions. Panel C:
column graph showing the distribution of secondary structures for the two peptides at 20% of
TFE. Panel D: the changes in the composition of ordered structures (i.e. helix and strand) for
each peptide with TFE concentration.

To further confirm the structural impact of lysine acetylation on the H4 sequence, we
conducted a simulation analysis of the unacetylated H4 and tetraacetylated H4 peptides. The
modeling was conducted on the Jaguar parallel machine by using the AMBER suite of programs.
The simulations show that a dramatic structural change occurs upon lysine acetylation. The first
evidence for the structuring effect of tetra-acetylation is provided by the distribution of the radius
of gyration plot (Figure 5.9a). This distribution appears relatively flat and broad (average: 12.16
Å, variance: 6.06 Å2) in the case of the wild-type peptide but undergoes a shift towards lower
values when the peptide is acetylated. This observation is suggestive of a transition from a
population of extended, predominantly random coil peptides to a population of compact and
more globular structures. Figure 5.9b shows that in the wild type peptide, the distribution of the
pairwise backbone RMSD had an average of 7.67 Å and a variance of 4.20 Å2. These values shift
to 4.93 Å and 2.36 Å2 respectively for the acetylated peptide suggesting that acetylation creates a
more homogeneous population with a smaller number of structural families. This prediction is
confirmed by clustering analysis where a cutoff as large as 9.0 Å was necessary to group the wild
type population into 14 clusters whereas a cutoff of 6.0 Å was sufficient to generate 18 clusters
in the case of the acetylated peptide.
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Figure 5.9. Simulated structural changes upon tetraacetylation of the N-terminal H4
tail. Panel (a): Probability distribution of the radius of gyration of the unacetylated and tetraacetylated H4 peptides. Panel (b): probability distribution of the pairwise backbone RMSD of the
structures of the equilibrium population.

The clusters of the equilibrium population of the unacetylated peptide roughly belong to
three main structural groups whose representative conformations can be seen in Figure 5.10. The
first group (50% of structures) is mainly populated by extended conformations where lysine and
arginine side chains stick out from the axis of the molecule to minimize electrostatic repulsion.
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The second group (24% of structures) is populated by distorted hairpin-like conformations where
the standard β-hairpin is replaced by a swollen bubble-like loop arising from the repulsion
between lysines and arginines. Finally, the third group (26% of structures) comprises extended
conformations featuring a small loop at one or both ends that can be regarded as intermediates in
the interconversion pathway between the structures of the first two groups.

Figure 5.10. Clustering of the equilibrium population of the unacetylated (left
column) and tetraacetylated (right column) H4 peptides. Rows (a), (b), (c) show the
representative conformations of clusters 1, 2 and 3 respectively. The color code represents
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different secondary structural elements as identified throuh a DSSP analysis (156). Purple: αhelix; Blue: 310-helix; Green: turn; Orange: random Coil.

Three major classes can also be detected in the equilibrium population of the
tetraacetylated H4 peptide based on the results of the clustering analysis (Figure 5.10). The motif
of the first class, including 59% of structures, is represented by three 310 helices orthogonal to
each other and is therefore somewhat reminiscent of the hairpin-like conformations of group 2 of
the unacetylated peptide. It can therefore be suggested that acetylation induces the stabilization
and structuring of a conformation that was already present in the population of the unacetylated
species. As a final remark, we note that this motif brings the N- and C- termini of the H4 tail
peptide close to one another thus suggesting a possible mechanism through which the acetylation
of K16 affects the methylation propensity of R3 from a distal region of the molecule. The second
class, amounting to 24% of the structures, features extended conformations composed by two or
three 310 helices linked by turns. The third class (17% of structures) is characterized by an Lshaped motif composed by two orthogonal 310 helices linked by a central turn region, which,
similarly to the case of the unacetylated peptide, can be considered as intermediates between the
conformations of the former two classes. In fact, in conditions of dynamic equilibrium, it can be
suggested that the extended conformations of Class 2 can bend in the L-shaped conformation of
Class 3 which finally completes the folding in the orthogonal arrangement of helices of Class 1.
5.3. Conclusion
To dissect the interplaying relationship between different histone modification marks, we
investigated how individual lysine acetylations and their different combinations at the H4 tail
affect Arg-3 methylation in cis. Our data reveal that the effect of lysine acetylation on arginine
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methylation depends on the site of acetylation and the type of methylation. While certain
acetylations present a repressive impact on PRMT-1 mediated methylation (type I methylation),
lysine acetylation generally is correlated with enhanced methylation by PRMT5 (type II
dimethylation). In particular, Lys-5 acetylation decreases activity of PRMT1 but increases that of
PRMT5. Furthermore, circular dichroism study and computer simulation demonstrate that
hyperacetylation increases the content of ordered secondary structures at the H4 tail region.
These findings provide new insights into the regulatory mechanism of Arg-3 methylation by H4
acetylation, and unravel that complex intercommunications exist between different PTM marks
in cis. The divergent activities of PRMT1 and PRMT5 with respect to different acetyl-H4
substrates suggests that type I and type II PRMTs use distinct molecular determinants for
substrate recognition and catalysis.
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Figure 5.11. Summary of the effects of lysine acetylation on R3 methylation in H4.
Acetylation of the N-terminal H4 tail reciprocally affects PRMT1-mediated Arg-3 methylation
and PRMT5-mediated Arg-3 methylation. A solid line means that the effect of acetylation is
appreciably strong and a dotted line means that the effect of acetylation is relatively weak.
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5.4. Experimental
5.4.1. Design and synthesis of acetylated H4 peptides
The amino-terminal peptide of histone H4 containing the first 20 amino acid residues and
different acetylation patterns were synthesized using Fmoc [N-(9-fluorenyl) methoxycarbonyl]based solid phase peptide synthesis (SPPS) protocols on a PS3 peptide synthesizer (Protein
Technology. Tucson, AZ). Each amino acid was coupled to the solid phase by using 4
equivalents

of

amino

acid/HCTU

[O-(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-

tetramethyluronium hexafluorophosphate] (Novabiochem, Darmstadt, Germany). Fmoc was
deprotected with 20% v/v piperidine/DMF. The N-terminal amino acid was acetylated with
acetic anhydride. The peptide was cleaved from the Wang resin by incubating the resin in a
cleavage solution consisted of 95% trifluoroacetic acid (TFA), 2.5% H2O and 2.5%
triisopropylsilane for 3 h. Peptides were precipitated in cold ether and then pelleted by centrifuge
at 3000 RPM for 10 min. After washing with ether, crude peptides were collected and purified
using a Varian Prostar instrument equipped with a C-18 Reversed-phase High Performance
Liquid Chromatography (RP-HPLC) column. 0.05% TFA-containing water and 0.05% TFAcontaining acetonitrile were two mobile phases used in gradient purification. The purity and
identity of purified peptides were confirmed by analytical HPLC and MALDI-MS.
5.4.2. Calibration of peptide concentrations with NMR
The accurate concentration of each peptide was determined by measuring its 1D 1HNMR spectra with external standard on a Bruker Avance 400 MHz instrument. For each NMR
sample, a D2O solution was prepared containing 4.5 mM (weight-based) of individual H4
peptide and 1 mM of 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS), respectively. The 1H
NMR spectra were collected at room temperature. The integration ratio between the proton peak
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of DSS at 0 ppm and the two proton peaks of the imidazole group of the histidine residue, i.e.,
His-18 (δ = 7—9 ppm) was measured to calculate the real concentration of each H4 peptide
sample.
5.4.3. Protein expression and purification
Recombinant His-tagged rat PRMT1 was expressed in E. coli and purified with Nicharged His6x-tag binding resin (Novagen). The PRMT1-pET28b(+) plasmid was transformed
into E. coli BL21(DE3) (Stratagene) by heat shock. Bacteria were incubated in LB media at 37ºC
for growth, and 16 ºC for protein expression (induced by IPTG 0.3 mM). Cells were harvested by
centrifuge and lysed by French Press. The supernatant containing PRMT1 protein was loaded to
the Ni-charged His6x-tag binding resin equilibrated with column buffer (25 mM Na- HEPES, pH
7.0, 300 mM NaCl, 1 mM PMSF, and 30 mM imidazole). Beads were washed thoroughly with
column buffer and washing buffer (25 mM Na- HEPES, pH 7.0, 300 mM NaCl, 1 mM PMSF,
and 70 mM imidazole), and eluted with elution buffer (25 mM Na-HEPES, pH 7.0, 300 mM
NaCl, 1 mM PMSF, 100 mM EDTA, and 200 mM imidazole). Different eluents were checked
by 12% SDS-PAGE. After dialysis and concentrating, protein concentration was determined by
Bradford assay. Active flag-tagged human recombinant PRMT5/MEP50 was purchased from
BPS Bioscience, Inc.
5.4.4. Radioactive methylation assays
The methylation assays of different H4 peptide substrates were performed using

14

C-

isotope labeled AdoMet at 30°C. The typical reaction buffer contained 50 mM HEPES (pH=8.0),
10 mM NaCl and 1 mM DTT. Peptide substrate and [14C]-AdoMet were preincubated in the
reaction buffer for 5 min prior to the initiation of methyl transfer reaction by the addition of
PRMT. The reaction time was controlled under initial condition so that the typical reaction yields
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were within 15%. The reaction was quenched either by spreading the reaction mixture onto P81
filter paper disc (Whatman) or by mixing the reaction buffer with 5x protein-loading dye. For the
filter-binding assay, the paper discs were washed with 50 mM NaHCO3 (pH 9.0) and air dried
for 2 h, and then liquid scintillation was conducted to measure the amount of methylated
products. For the gel-based assay, methylation mixtures were resolved on 16% SDS-PAGE and
the gel was dried and exposed to phosphor film for at least 36 h in dark. The phosphorimage was
scanned on Typhoon 9400 scanner and the amount of methylated products was quantitated with
ImageQuant program (GE healthcare). Data of Km and kcat were obtained with the filter binding
assay by measuring the initial velocity of reaction at varied concentrations of one substrate and
fixed saturating concentration of the other substrate, and fitting the kinetic data with MichaelisMenton equation.
The methylation assays were also conducted for histone H4 protein and reconstituted
nucleosomes to confirm the effect of H4 acetylation on its methylation by PRMT1 and PRMT5.
Recombinant human core histones were purchased from New England Biolabs and reconstituted
nucleosomes were assembled using the EpiMark assembly kit. The protein substrate was
incubated with acetyl-CoA (20 μM) in the absence or presence of p300 or MOF (0.4 μM) in the
reaction buffer (50 mM HEPES (pH = 8.0), 50 mM NaCl, 1mM EDTA, and 0.5 mM DTT) at
30°C for 10 min. Then [14C]-AdoMet (15μM) and PRMT1 (0.01 μM) or PRMT5 (0.1 μM) were
added into the reaction mixture to initialize H4 methylation. The methylated protein was
separated on SDS-PAGE (15 % for H4 protein and 17 % for nucleosome) and visualized by
storage phosphor imaging.
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5.4.5. Circular Dichroism (CD) measurement and analysis
Secondary structures of unacetylated H4 peptide and tetraacetylated H4 peptide at
different concentrations of TFE were studied with CD on a Jasco J-810 spectropolarimeter. A 1mm CD cell with 200 μL of peptide sample (in 20 mM Tris buffer, pH 7.4) with 0 ~ 80% of
2,2,2-trifluoroethanol (TFE) was loaded to the CD spectrophotometer. Nitrogen pressure was
kept constant around 100 kPA. CD spectra of peptides were scanned from 260 nm to 190 nm
with standard sensitivity, 0.5 nm data pitch, 1 nm band width, 100 nm/min scanning speed, and
10-time accumulation. The concentrations of peptides were selected to keep the negative peak
value of ellipticity in-between -10 mdeg to -30 mdeg. CD spectra were saved as text file (Jasco
1.30) and submitted to Dichroweb, an online server for protein Circular Dichroism spectra
deconvolution (154). Dichroweb incorporates five open source algorithms (Contin-LL, Selcon 3,
CDSSTR, VARSSLC, and K2d) to calculate protein secondary structure content. Of these five
algorithms, Provencher & Glockner Method (Contin-LL) and Self Consistent Method (Selcon 3)
were chosen to determine the percentage of secondary structural components (helix, strand, turn,
and random coil) of each peptide sample.
5.4.6. Structure simulation for the unacetylated and tetraacetylated H4 peptides
The modeling was conducted on the Jaguar parallel machine at the Oak Ridge Leadership
Computing Facility by using the AMBER suite of programs. The wild-type and tetraacetylated
H4 peptide were parameterized using the Antechamber (157) program with BCC charges. His-18
of the wild type peptide was recognized to be in the epsilon-protonation state through an H-bond
network

analysis

carried

out

using

the

WHATIF

server

(158)

(http://swift.cmbi.ru.nl/servers/html/index.html). The same protonation state was assigned to the
histidine of the tetraacetylated peptide since the presence of non-standard acetylated lysine
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residues prevented the use of WHATIF. Replica exchange (REMD) simulations have been
performed with the Amber10 suite (159) of programs using the force field ff99SB (160) and the
GB-neck solvent model (161) with a 0.2 M concentration of monovalent ions and a dielectric
constant of 78.5 (corresponding to water). Both the wild type and the acetylated peptides
underwent 200 steps of steepest descent minimization followed by 200 steps of conjugate
gradient minimization. Twenty replicas of the minimized system were then created and gradually
heated to their target temperatures in a short 1 ns NPT run using Langevin dynamics with a
collision frequency of 1.0 ps-1. The temperatures of the replicas were chosen in geometric
progression to ensure uniform exchange probability for all pairs of temperatures (the values for
the temperature T (in K) was set to 300, 314, 330, 345, 362, 380, 398, 417, 437, 458, 480, 503,
528, 553, 580, 608, 637, 668, 700 and 734). A 105 ns REMD simulation was then carried out:
the first 5 ns of the simulation were discarded and analysis was performed on a set of 1976
structures for the wild type and 1722 structures for the acetylated peptide, respectively. The
structures, sampled at intervals of 50 ps along the T = 300 K trajectory, were then clustered using
a quality threshold clustering algorithm (162). Secondary structure analysis was performed using
the DSSP algorithm (156)
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CHAPTER 6
SUMMARY
Posttranslational modifications (PTMs) are important strategies used by eukaryotic
organisms to modulate their phenotypes. One of the well studied PTMs, arginine methylation, is
catalyzed by protein arginine methyltransferases (PRMTs) with SAM as the methyl donor. The
functions of PRMTs have been broadly studied in different biological processes and diseased
states like cancer and heart disease, suggesting them as potential therapeutic targets, but the
molecular basis for arginine methylation is not well defined. To unravel the molecular
mechanism of arginine methylation and facilitate the rational design of PRMT inhibitors, we
explored several strategies to study the activity and inhibition of PRMT1, the predominant
PRMT in mammalian cells.
1. New fluorescent reporters were designed and applied to perform single-step analysis
of substrate binding and methylation by PRMT1. Both fluorescence intensity and anisotropy
of the two reporters, R4-FL and H4-FL, were shown to effectively manifest enzyme-substrate
interactions, highlighting their application in investigating PRMT inhibitors. In particular, the
methylation process of R4-FL can be directly studied using fluorescence intensity readout. By
combining the fluorescent measurement with radioactive analysis, we determined that AMI-1
inhibits PRMT1 activity through the mechanism of blocking peptide substrate binding.
Furthermore, we showed that the fluorescence intensity of R4-FL is sensitive to the
progression of both substrate binding and methylation, suggesting that it will be a useful
fluorescent probe to investigate the transient kinetic mechanism of PRMT catalysis. Given
that GAR motif-containing sequence is a common feature of many PRMT substrates,(23) R4-
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FL is not only a fluorescent reporter of PRMT1, but may also be applicable to other PRMT
members.
2. Malfunction of protein arginine methyltransferases (PRMTs) is correlated with many
human diseases. Thus, small molecule inhibitors of protein arginine methylation are of great
potential for therapeutic development. In out study, we have discovered a type of organic
compounds containing naphthalene and sulfonyl pharmacophore components that inhibit PRMT
activity in the micromolar range, whose inhibition mechanism is fundamentally distinct from the
other PRMT inhibitors reported so far. The biochemical and biophysical data of representative
compounds show that these inhibitors are competitive versus PRMT1 substrates (e.g., H4 and
GAR peptides) and noncompetitive versus the methyl donor. Detailed studies illustrate that they
directly target the peptide substrates instead of PRMT1, and the binding subsequently blocks the
recognition of the substrates by the enzyme, which is largely responsible for the observed
PRMT1 inhibition effect. We also show that the anti-parasitic drug suramin is also an effective
arginine methylation inhibitor. These NS inhibitors will be useful chemical tools for mechanistic
study of arginine methylation and other epigenetic modifications. Further, illumination of the
inhibitory mechanism provides a new insight for understanding the pharmacological effect of
these structurally unique molecules in biological systems.
3. The biological functions of PRMTs have been shown to be involved in diverse
biological processes and diseased states, yet the molecular basis for arginine methylation is
unclear. In our study, we performed the transient-state kinetic analysis of PRMT1 catalysis. Our
stopped-flow fluorescence data provide a detailed view of arginine methylation catalyzed by
PRMT1. According to our result, the methyl transfer step is the major rate-limiting step which
proceeds much slower than substrate association and product release. Binding of the cofactor
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SAM/SAH appreciably affects the interaction between H4 peptide and the enzyme, probably due
to a conformational change upon enzyme-cofactor complex formation. Importantly, the transient
kinetics data reveal a conformational transition step following the substrate binding and prior to
the chemical step. This protein isomerization likely reorganizes the active site of PRMT1,
bringing the side-chain terminal nitrogen of H4R3 in close proximity to the reactive methyl
group of SAM and facilitating the methyl transfer. These results provide new insights into the
molecular mechanism of arginine methylation and the rational design of PRMT inhibitors.
4. Epigenetic crosstalk has become a very popular research area recently. To dissect the
interplaying relationship between different histone modification marks, we investigated how
individual lysine acetylations and their different combinations at the H4 tail affect Arg-3
methylation in cis. Our data reveal that the effect of lysine acetylation on arginine methylation
depends on the site of acetylation and the type of methylation. While certain acetylations present
a repressive impact on PRMT-1 mediated methylation (type I methylation), lysine acetylation
generally is correlated with enhanced methylation by PRMT5 (type II methylation). In particular,
Lys-5 acetylation inhibits activity of PRMT1 but promotes that of PRMT5. Furthermore, CD
study and computer simulation demonstrate that hyperacetylation increases the content of
ordered structures at the H4 tail region. These findings give new insights into the regulatory
mechanism

of

Arg-3

methylation

by

H4

acetylation,

and

unravel

that

complex

intercommunications exist between different PTM marks in cis. The divergent activities of
PRMT1 and PRMT5 with respect to different acetyl-H4 substrates suggests that type I and type
II PRMTs use distinct molecular determinants for substrate recognition and catalysis.
Our data about the divergent impacts of acetylation on R3 methylation, e.g., K5
acetylation represses while K16 acetylation enhances R3 asymmetric di-methylation, also

120

provide insights into the function of HATs. Many acetylated H4 isoforms, especially the one
containing K16ac, favors R3 methylation by PRMT1. Therefore, certain H4 acetylation marks
are compatible with type I methylation of R3. Recent MS analysis of H4 protein in
differentiating human embryonic stem cells revealed that K16 was the most abundant acetylated
residue and K16ac and K5ac rarely occurred on the same histone H4 molecule, indicating that to
some extent, these two acetylations are mutually exclusive and likely have distinct functions
(139). This is consistent with previous notions that K16 acetylation has distinct function from the
acetylation of other lysine residues at the H4 tail, including K5ac (163, 164). Given that PRMT1mediated R3 methylation is associated with gene activation, it may be that K5 acetylation has
repressive and K16 acetylation has activating function in gene regulation. Although histone
acetylations are generally considered as gene activation marks, they might also be able to exhibit
repressive function under certain contexts by fine tuning its site specificity at the histone tail with
balanced usage of counteractive PTM marks such as K5ac and K16ac. Although a quantitative
correlation of the exact linkage of individual H4 acetylation marks to transcriptional on/off status
needs to be investigated in the future, a few studies indeed suggest that histone acetylation may
possess repressive function in gene expression regulation in certain contexts (165-168).
5. Indication from the assembled nucleosome methylation assay.
In the study of accetylation effect on histone methylation, we found that H4 protein in the
context of nucleosome or even in the presence of DNA (2:1 ratio as is in the nucleosome) was
not appreciably methylated by PRMT1 or PRMT5 in our reaction conditions. The physiological
substrate, nucleosome, has difficulty to be methylated by PRMT1/5. This important observation
implicates that DNA (especially the unassembled free DNA) poses a physical barrier between
nucleosomal histone and PRMTs, preventing the N-terminal tails of the core histones from being
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recognized by PRMTs. In another way, the negatively charged DNA and the acidic suface
grooves on PRMT1 may compete with each other to bind the the positively charged histones. In
the cells, although the histone tails extend out from its nucleosome core and adopt a free, flexible
sturcutre, they can also possibly interact with link DNA from another nucleosome or another
chain. Quite likely, arginine methylation of the chromatin template by PRMTs would require
additional accessory proteins or factors in vivo to release the interaction between DNA and
histones and give access for PRMT binding. Another possibility is that the 5SrDNA used in our
assay is not well-suited for nucleosome assembly. If we switch to another nuclear DNA fragment
the methylation result could be different. This DNA effect should be further investigated.
6. Salt effect on the interaction between NS-1 and H4-20.
The NaCl salt effect on the interaction between H4-20 and NS-1 were tested with UV-Vis
spectral chance and PRMT1 inhibition assay. From Figure SI-6, mixing of 5 μM H4-20 peptide
induces a big change in the UV-Vis spectrum of 40 μM NS-1 (maximum absorption reduced
nearly by half), but adding of 0 ~ 300 mM NaCl introduces very little change to the absorption of
the mixture. Thus NaCl concentration has little effect on H4-20-NS-1 interaction. The inhibition
effect of NS-1 on PRMT1 activity was also tested with varied NaCl concentration in the
radioactive methylatioin assay (Figure SI-7). PRMT1 activity is negatively affected by NaCl
concentration when it goes above 150 mM. If NS-1-H4-20 interaction is weakened by salt effect,
we would expect to see an increase in PRMT1 activity when NaCl goes higher. Yet when NaCl
ranges between 0 to 150 mM, the inhibition effect of NS-1 does not change much with NaCl
concentration. Again this leads to the conclusion that the salt effect appears to be very minor,
indicating that charge-change interaction is not the major driving force for H4-20-NS-1
associtation. The hydrophobic interactions, H-bonding, or π-π stacking may play more important
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roles here. As changing the substrate to H4(1-11) increased the IC50 of NS-1 significantly, we
propose that the C-terminal and N-terminal residues are both required for efficient binding.
According to the fluorescent titration with job’s method, NS-1 and H4(1-20) showed a 1:1
binding ratio, thus the association should be specific instead of nonspecific charge-charge
interaction.
7. The enzyme-substrate interaction speculation from the modeled peptide and the crystal
structure of PRMT1.
We think that PRMT1 competes with DNA for binding to histones. Acid residues (20
Asp and Glu) are predominant on the surface of PRMT1, forming several acid grooves which are
supposed to generate an initial binding affinity for positively-charged substrates. Surfacescannng mutagenesis study indicated that some of these negatively charged residues were
important for substrate specificity (E47, E129, and E236), substrate binding (E46 and D51),
dimerization/oligomerization, or transcription coactivator function (31). In the crystal structure,
the electron densities of bound peptide substrates were broken into three separate fragments.
Other than the arginine bound in the active site, the amino acid residues of the peptide were not
clearly identified due to low resolution of side chain densities. A mixture of peptide binding
modes was proposed from the three disconnected densities. The fact that multiple substrate
binding grooves exist on the surface of PRMT1 may explain why PRMT1 methylates diverse
protein substrates. The negatively charged C terminus is close to the active site and may play an
important role for substrate binding or catalysis.
Our biochemical data reveal that the impact of H4 acetylation on PRMT1-mediated R3
methylation depends on the individual pattern of acetylation. The clear observation is that K5ac
is the predominant modification mark that negatively impacts R3 methylation by PRMT1. The
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lower kcat of H4K5ac methylation with regard to that of the wild type H4 suggests that the acetyl
group on K5 produces a steric or hydrophobic hindrance in the active site, reducing the ability of
PRMT1 in methylating H4R3. Interestingly, K16ac enhances R3 methylation, and to some
degree antagonizes the effect of K5 acetylation. The observed acetylation effect suggests
valuable clues about PRMT1-H4 interaction. It seems reasonable that K16ac affects Km, but not
kcat, given the remoteness of this residue to R3 along H4 backbone. The prominent impact of
K16 acetylation on R3 methylation is in good agreement with a previous study showing that the
basic amino acid residues on the H4 tail distal from R3 (i.e., aa 16-20) interact with PRMT1 and
contribute to substrate recognition (153). The crystal structure of PRMT1 highlights that an
acidic area exists on the surface of PRMT1 (80) and suggests that positive charges of substrates
are needed for binding to the enzyme. Here, our data demonstrate that electrostatic interaction
does not seem to be the sole factor determining the PRMT1⎯substrate interaction since K16
acetylation favors the methylation at R3. Upon tetra-acetylation, the structural modeling shows
that H4 tail forms a more regular and bended conformation, likely bringing K16 closer to the
target arginine and affecting the peptide binding with PRMT1. The extra acetyl group on K16
may increase the hodrophobic contact or provide one more H-bond to a PRMT1 binding groove
compared to the unacetylated, extended H4 peptide, thus lowering the Km.
On the other hand, the acetylation effect on R3 methylation is quite opposite for PRMT5
catalysis. We propose that PRMT5 likely has a larger binding pocket connected with the active
site than PRMT1 to accommodate the acetyl group on Lys 5 close to Arg 3. This acetyl group
may provide more hydrophobic or H-bond interaction with PRMT5 to increase its binding
affinity. Thus compared with wild-type H4(1-20), H4K5ac become a better substrate for PRMT5
and a worse substrate for PRMT1.
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An effort is put to gain the crystal structure of PRMT1 fused with H4(1-20) to analyze
the detailed binding mode.
8. A discussion of type I and type II PRMT catalytic mechanism and a summary of how
our discovery fits into the context of current understanding of arginine methylation.
So far the only proposed catalytic mechanism of PRMT1 according to its crystal structure
is that the two invariant active site glutamates fix the positive charge on the guanidine group on
the δ and one of the ω nitrogens, so that the lone pair of electrons left on the other ω nitrogen can
attack the active methylsulfonium group of SAM in close proximity. The attacking guanidine
nitrogen is deprotonated by a His-Asp relay system. Possibly an active site structural
rearrangement can help stablize the positively charged transition state, lowering the energy gap
between the ground state and the transition state thus facilitating the reaction. The active site pH
environment is important for catalysis, which puts electrostatic and steric requirements for the
residues besides the target arginine. The detailed catalytic mechanism of type II PRMTs is still
unkown due to lack of crystal structure of the enzyme-substrate-cofactor ternary complex.
Recently the structure of C. elegans PRMT5 (CePRMT5) with bound SAH was reported. The
mutagenesis study suggested that a conserved phenylalanine (Phe 379 for CePRMT5) in the
active site of PRMT5 is critical for directing the symmetric di-methylation, as mutating of Phe
379 to methionine (as in PRMT1) led to genetration of both symmetric and asymmetric
dimethylated arginines. (17) Thus type I and type II PRMTs are likely to share a similar catalytic
mechanism with different active site steric groups. Phe 379 is located on helix αA which
becomes more structured upon the cofactor binding. The steric constraint placed by Phe 379 and
possibly other residues should be important for PRMT5 product specificity. Yet we still don’t
know exactly how the target arginine is bound in the active site (defined by E499, E508, F379,
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K385, S503, and S669 in CePRMT5). It is possible that the two essential acidic residues (E499
and E508) bind to the guanidinium δ and ω nitrogens in a similar manner as for PRMT1 to
facilitate the methyl transfer. But after one methyl group is added, there is not enough space for
the same ω nitrogen to accept another methyl group due to steric hindrance produced by Phe
379, etc. So the monomethylated arginine has to rotate the side chain and likely rebind to another
enzyme active site with switched positions of the two ω nitrogens for the free one to get
methylated. Therefore, with the steric restriction in the active site, type II PRMTs can only
catalyze the formation of symmetrically dimethylated arginines. But with a methionine in the
position of the conserved phenylalanine, PRMT1 has a more flexible active site structure to
accommodate two methyl groups on one ω nitrogen. Furthermore, from the above point of view,
type II PRMTs are more likely to follow a distributive mechanism rather than a processive
mechanism, similar as what we experimentally suggested for PRMT1.
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Figure 6.1. The active site of PRMT5 (PDB 3UA3).
Our kinetic data suggests that PRMT1 has to form a ternary complex with the substrate
and the cofactor to transfer the methyl group. The catalytic mechanism is by bringing the two
substrates in close proximity to facilitate the nucleophilic attack. The transient state kinetic data
indicate that PRMT1 transfers two methyl groups following a distributive mechanism, that the
chemical step of methyltransfer is rate-limiting, that cofactor binding causes an enzyme
conformational change which increases its affinity for the substrate, and that substrate
association leads to another conformational transition that likely covers the active site and brings
the target arginine closer to the active methyl group of SAM for the nucelophilic attack. This
may be acomplished by movement of the double-E loop connecting strand β4 and helix αD
towards the target arginine of the peptide to bury it in the active site. To confirm these
hypotheses, the crystal structures of the apo enzyme, the holoenzyme and the enzyme-cofactorsubstrate ternary complex should be compared.
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APPENDIX
Table SI-1. Inhibitory data of the fifty top-ranked compounds obtained from the
virtual screening. In a typical assay, the reactions were carried out at 30°C with 0.1 μM of 6xrPRMT1, 5 μM of [14C]-AdoMet, and 2 μM of H4(1-20), in the presence of 100 μM of
individual inhibitors.

Compound ID

Retained fractional
activity of PRMT1

Compound ID

Retained fractional
activity of PRMT1

7395064

100

6117046

100

5310809

100

7736131

100

5794588

100

RJC 03491

100

6877387

103

7558583

100

6381790

98

5650276

93

5839065

99

5839747

98

6278455

91

5767214

100

7848611

95

7071534

100

5689130

100

6715339

100

5838031

100

HTS 06914

100

6244071

100

5845246

100

6274859

100

JFD 00459

100

6300962

120

6764997

99

5718222

100

7340109

98

6944291

100

5837758

108

7245849

100

5839847

100

5755262

100

7730013

121

6097286

100

6911199

94

7786009

120

5706616

100

5836899

100

6746073

100
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CD 10984

100

7789764

100

SEW 03621

100

5847891

100

5843933

90

6722670

92

5688743

100

KM 08497

100

6498204

100

2

80

Table SI-2. IC50 of selected compounds for the inhibition of GST-hPRMT1.
Radioactive methylation assay conditions were the same as described for the inhibition of His6xrPRMT1, except for longer reaction time. The typical reaction mixture contained 2 μM of H4(120), 5 μM of [14C]-AdoMet, 0.1 μM of GST-hPRMT1, and increasing concentrations of
individual inhibitor.

compound #

IC50 (μM) to GST-hPRMT1

3

12.9 ± 0.2

4

50.5 ± 0.5

5

68.2 ± 1.0

6

121.7 ± 7.8
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1

91.2 ± 4.9
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Figure SI-1. Structures and inhibition data of the rest of selected analog compounds.
The inhibition assays were performed using His6x-rPRMT1 (0.1 μM), [14C]-AdoMet (5 μM),
and H4(1-20) (2 μM). The potencies of these compounds are much weaker than compounds
3→11.c
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Figure SI-2. Fluorescent competitive binding of 3 to R4-FL. (a) Fluorescence
anisotropy (524 nm) of R4-FL solution at different concentrations of PRMT1. The concentration
of R4-FL was fixed at 0.2 μM. (b) Fluorescence anisotropy (524 nm) of R4-FL and PRMT1
complex at different concentrations of 3. The total concentration of R4-FL and PRMT1 was 0.2
μM and 2.0 μM respectively.
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Figure SI-3. Kinetic analysis of 6 in the inhibition of PRMT1 plotted as doublereciprocal plots. a. Inhibition pattern of 6 at fixed [14C]-AdoMet (5 μM) and varied H4(1-20)
concentraions. The concentration of 6 was selected at 0 μM (♦), 50 μM (■), 100 μM (▲) and
150 μM (●) respectively. b. Inhibition pattern of 6 at fixed H4(1-20) (2 μM) and varied [14C]AdoMet concentraions. The concentration of 6 was fixed at 0 μM (♦), 50 μM (■) and 100 μM
(▲) respectively. 0.03 μM of His6x-rPRMT1 was added in all these assays.
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Figure SI-4. Stilbamidine and 6 compete with the substrate for binding to PRMT1.
Fluorescence anisotropy (524 nm) of R4-FL─PRMT1 complex at different concentrations of
stilbamidine (a) or 6 (b) was measured. The concentration of R4-FL and PRMT1 was fixed at 0.2
μM and 2.0 μM, respectively, for both titrations.
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Figure SI-5. CD study of H4(1-20) association with 3. 100 μM of H4(1-20) was titrated
with 0 μM (∆), 100 μM (♦), and 200 μM (●) of 3 in 10 mM of Tris buffer (pH 7.4). CD
spectrum change of H4(1-20) was monitored. The secondary structural data cannot be analyzed
due to the formation of precipitate (H4(1-20) – compound 3 complex).
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Figure SI-6. Salt effect on the UV-Vis spectrum of NS-1▬H4-20 complex. 40 μM
NS-1 and 5 μM H4-20 were mixed in the reaction buffer (50 mM HEPES (pH 8.0), 1 mM
EDTA, 0.5 mM DTT) containing different concentrations of NaCl (0, 15, 75, 150, 300 mM). The
UV-Vis spectra (700 nm ~ 280 nm) were taken on a Shimadzu UV-1700 spectrophotometer. 1.
Reaction buffer; 2. 40 μM NS-1 in the reaction buffer; 3. 40 μM NS-1 + 5 μM H4-20 + 0 mM
NaCl; 4. 40 μM NS-1 + 5 μM H4-20 + 15 mM NaCl; 5. 40 μM NS-1 + 5 μM H4-20 + 75 mM
NaCl; 6. 40 μM NS-1 + 5 μM H4-20 + 150 mM NaCl; 7. 40 μM NS-1 + 5 μM H4-20 + 300 mM
NaCl.
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Figure SI-7. Salt effect on the inhibition of NS-1 on PRMT1 activity. 2 μM H4-20 and
5 μM 14C-SAM were mixed with 20 μM NS-1 in the reaction buffer (50 mM HEPES (pH 8.0), 1
mM EDTA, 0.5 mM DTT) containing different concentrations of NaCl (0, 18.75, 37.5, 75, 150,
300 mM). 0.1 μM PRMT1 was added to initiate the methyltransfer reaction which lasted for 8
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min at 30 °C. The reaction was quenched by loadint the mixture onto P81 paper and the products
were quantified by liquid scintillation.

substrate
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KRK
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k1/min‐1 * M‐2
0.076 ± 0.004
0.010 ± 0.00077
0.0031 ± 0.00026
0.00031 ± 0.000011
0.000011 ± 0.00000031

k2/min‐1 * M‐2
0.23 ± 0.03
0.013 ± 0.0013
0.0044 ± 0.00052
0.00063 ± 0.000039
0.000028 ± 0.0000015
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Figure SI-8. Relative abundance of peptide changes as a function of time during the
methylation reaction by rPRMT1. Data was derived from relative intensity of peaks in
MALDI-MS analysis.

136

Figure SI-9. Scheme of the radioactive HMT assay.
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Figure SI-10. Sequential Bi-substrate Binding Model of PRMT1 with H4 and SAM.
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Mass spectra for peptides
1. CGG-H4(1-21)FL
4700 Reflector Spec #1 MC[BP = 441.1, 27577]
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4700 Reflector Spec #1 MC[BP = 2494.5, 2025]
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